**Name of journal: World Journal of Transplantation**

**ESPS Manuscript NO: 11470**

**Columns:** **FRONTIER**

What’s new in clinical solid organ transplantation by 2013

Salvadori M *et al*. News in transplantation

Maurizio Salvadori, Elisabetta Bertoni

**Maurizio Salvadori, Elisabetta Bertoni,** Deparment of Transplantation, Careggi University Hospital, 50139 Florence, Italy

**Author contributions:** Salvadori M and Bertoni E contributed equally to conceivement, finding materials, writing and reviewing this paper.

**Correspondence to: Maurizio Salvadori, MD, Professor** of Nephrology, Deparment of Transplantation, Careggi University Hospital, viale Pieraccini 18, 50139 Florence, Italy. [maurizio.salvadori1@gmail.com](mailto:maurizio.salvadori1@gmail.com)

**Telephone:** +39-055597151 **Fax:** +39055597151

**Received:** May 22, 2014  **Revised:** July 11, 2014

**Accepted:** July 27, 2014

**Published online:**

**Abstract**

Innovative and exciting advances in the clinical science in solid organ transplantation continuously realize as the results of studies, clinical trials, international conferences, consensus conferences, new technologies and discoveries. This review will address to the full spectrum of news in transplantation, that verified by 2013. The key areas covered are the transplantation activity, with particular regards to the donors, the news for solid organs such as kidney, pancreas, liver, heart and lung, the news in immunosuppressive therapies, the news in the field of tolerance and some of the main complications following transplantation as infections and cancers. The period of time covered by the study starts from the international meetings held in 2012, whose results were published in 2013, up to the 2013 meetings, conferences and consensus published in the first months of 2014. In particular for every organ, the trends in numbers and survival have been reviewed as well as the most relevant problems such as organ preservation, ischemia reperfusion injuries, and rejections with particular regards to the antibody mediated rejection that involves all solid organs. The new drugs and strategies applied in organ transplantation have been divided into new way of using old drugs or strategies and drugs new not yet on the market, but on phase I to III of clinical studies and trials.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** News in transplantation, kidney transplantation, pancreas transplantation, Liver transplantation; Heart transplantation; Lung transplantation; New immunosuppressant; Tolerance

**Core tip:** Basic and clinical science in solid organ transplantation are continuously evolving. In this review we outlined the most important innovative findings recently discovered. The period of time chosen was 2013, but attention has been paid to the outstanding conferences held in 2012, but published in 2013, as well as to the conferences and meetings held in 2013 but published in 2014. We are aware that when this study will be published, new interesting and relevant findings will have been discovered. The science is flowing continuously, nevertheless analyzing in depth a short period of time can give useful information to the readers.

Salvadori M, Bertoni E. What’s new in clinical solid organ transplantation by 2013. *World J Transplant* 2014; In press

**INTRODUCTION**

Innovative and exciting advances in the clinical science in organ transplantation continuously realize as the results of studies, clinical trials, international conferences, consensus conferences, new technologies and discoveries. This review will address to the full spectrum of the news in transplantation, that verified by 2013 and the key areas covered for every organ as the organ transplant activity, the organ survival rates, the organ preservation and allocation, the new immunosuppressive regimens, the new immunological findings and the most important complications following organ transplantation.

The organ procurement transplant network/scientific report transplant recipients (OPTN/SRTR), the most wide and extensive registry on transplantation, by the end of 2013 published the complete data[1] concerning organ transplantation for 2012 and allowed for several considerations on the transplant activity. In particular, in the 2013 report, for the first time, OPTN/SRTR has undertaken to publish the worldwide transplant rates as part of its annual data report[2].

This report found that the transplant counts and rates vary among the countries around the world for different reasons: (1) Differences in the rates of end-organ disease. Country to country variability in the underlying incidence of end-organ disease can be expected to affect the organ transplant rate. However other factors undoubtedly play a role in determining the transplant rates. For example the incidence of end stage renal disease (ESRD) in Norway in 2009 was one third of the incidence in the United States. Nevertheless, in 2010, the rates of kidney transplant were similar in Norway and the United States, probably due to the very high activity related to living donor that characterizes the Norway; (2) Socioeconomic factors. There is a strong correlation between the Human Development Index (HDI) and the rate of deceased and living donor kidney transplants among the world health organization (WHO) member states[3]. Similarly, the rates of liver transplant are lower in the countries with lower HDIs; (3) Cultural differences. An example is Japan that has a very high HDI, but lower rate of kidney transplants; and (4) Thoroughness of the transplant reporting, that varies by country.

Worldwide, use of living kidney donors varies widely, from less than 10% to more than 75% The rates of liver transplant have increased by more than 10% in several countries and declined in very few countries. In the past 5 years, the lung transplant rates have remained stable. The heart transplant rates changed little in the majority of countries.

**NEW INSIGHTS FOR DONORS**

In 2012 the number of deaths eligible for organ recovery for transplantation was lower than 2011 and 2010[4]. Similarly the mean number of organs transplanted per donor in US in 2012 was 3.02, lower than in 2011 and 2010. Numbers of hearts and lungs procured for transplant but not used are smaller than the numbers of kidneys, pancreas and livers because the former organs are recovered only after the acceptance by the transplant center.

Data from OPTN/SRTR show that the number of Standard Criteria Donors (SCD) have remained about the same in United States and Europe, but there has been a dramatic increase in older donors and organs classified as donation after cardiac death (DCD). Overall, among deceased donors there is an organ donor shift[5]. Indeed, the percentage of all donors who are SCD is on the decline and there is an increase in Expanded Criteria Donors (ECD).

This shift could impact on the outcomes and more research is necessary to improve the quality of organ used for transplant and to optimize the use of a further expanded donor pool.

A wide, retrospective study from Heaphy *et al*[6] confirms this issue, as the donor quality has significant interactions by race, primary diagnosis and age. Another study[7] suggests that the judicious use of ECD kidneys may be an appropriate strategy to expand the donor pool minimizing the effects upon the outcomes.

Improving the organ cold storage by machine perfusion (MP) has been proposed to improve the solid organ outcomes. Especially in liver[8], heart and lung transplantation[9], the MP seems to be a promising tool to improve post-operative outcome, but a general evidence-based recommendation for or against on application of MP, cannot be given due to the lack of highest level of clinical evidence.

In addition to the above mentioned shift among deceased donors (DD), recently, at least in United States, a decline in living kidney donation rate has been observed. This decline is about 13% per year and is more pronounced among blacks, men, younger adults, siblings and parents[10]. This fact warrants an action by transplant centers and national governments, also because another wide study[11] documented that the public is supportive of the living donation and in favor of protecting the health and safety of living donors.

A barrier to solid organ transplantation is often represented by the pre-transplant presence of donor specific antigens (DSAs) in the recipient sera. This fact is well known for the kidneys but has clinical relevance also for liver, heart and lung transplantation[12].

In such condition, for deceased donor kidney donation, the technique of acceptable human leukocyte antigen (HLA) mismatches has shown its efficacy. Two 2013 large studies proved its transnational efficacy[13, 14].

In the case of the living kidney donation the presence of preformed antibodies may represent a relevant barrier to transplantation. In kidney transplantation, this barrier may be overcome by the network called kidney paired donation (KPD). Originally conceived as simple two-way reciprocal exchange between AB0 incompatible, KPD has evolved to include complex, multicenter, discontinuous chains, with transcontinental transport of kidneys. To date the majority of the researches performed on KPD has involved computer generated mathematical optimization algorithms. Several 2013 papers confirm the effectiveness of such network[15-17].

**NEW INSIGHTS FOR KIDNEY**

Main kidney related issues considered in 2013 publications have been: the kidney and recipient graft survivals, the impact and consequences of ischemia-reperfusion injury, the antibody mediated rejection (ABMR) and the new techniques involved in rejection diagnosis.

***Transplant activity and kidney graft survival***

According OPTN/SRTR data, the shortage of kidneys for transplant remains a major problem for patients with ESRD. The number of candidates on the waiting list continues to increase, while the organ donation numbers remain flat[18]. Many kidneys recovered for transplant are then discarded for organ related problems and the discard rate is increasing. Living donation rates have been unchanged for the past decade. For both living and deceased donor recipients, the early post-transplant results have shown ongoing improvement.

For the first time, the graft survival rates have been systematically compared between Europe and United States. Utilizing data from OPTN/SRTR for United States and data from the Collaborative Transplant Study (CTS) for Europe, the 1, 5 and 10-year graft survival rates have been compared among Europeans and White, African and Hispanic Americans[19]. While the 1-year graft survival rate was similar, the 5 and 10-year graft survival rates were considerably higher for Europe than for any of the three United States populations. Differences increased beyond three to four years after transplantation and these differences are not explained by differences in baseline patient characteristics. Studies are needed to identify factors contributing to the observed graft survival differences. Previous studies have documented that the limitations in access to immunosuppressive medications[20, 21] and related compliance[22] are important determinants of long-term graft failure. Indeed, in the past the extension of immunosuppressive coverage in the US has shown to effectively reduce the income-related disparities in graft survival[23]. An United States study in 2013 examined the impact of Community risk factors on the kidney transplant outcomes[24]. The study documented that community risks are powerful factors associated with processes of care; and represent important considerations for developing effective interventions.

***Ischemia-reperfusion injury***

The Food and Drug Administration (FDA) held an open public workshop in September 2011 to discuss the current state of science related to the effects of ischemic reperfusion injury (IRI) on the outcomes in kidney transplantations. The summary of the workshop has been published in 2013[25]. The conclusions were that IRI impacts on graft survival and a better understanding of the underlying mechanisms is needed. Medical products to impact on IRI are urgently needed, but their development relies on both clinical and non-clinical researches. Also qualification of biomarkers is essential to elucidate the mechanisms[26].

Necroptosis in immunity and IRI have been principally studied in 2013[27-30]. Pathways of regulated necrosis (RN), an alternative to apoptosis have been recently described. The best studied RN pathway, the necroptosis, is triggered by perturbation of caspase-8-mediated apoptosis. In this condition the necroptosome is assembled and quickly leads to the necrotic-type cell death, release of the cell death-associated molecular patterns (CDAMPS) and severe organ damage. Interference with necroptosis (*e.g*., by necrostatin) is more likely to be of clinical benefit in situations in which the reperfusion damage can be anticipated as solid organ transplantation.

***Antibody-mediated rejection***

Recent studies indicate that antibody-mediated rejection (ABMR) is among the most important barriers to improving long term outcomes principally in kidney transplantation, but in other solid organs as well[31].

Additionally new knowledge in ABMR pathophysiology, classification, diagnostic techniques and therapeutic approaches has merged. While the new therapeutic approaches will be described in the therapy chapter, the other issues will be treated in this paragraph.

A relevant and new finding is that not only the donor specific antibodies anti HLA (DSAs-HLA) are involved in ABMR. The antibodies against other molecules[32, 33] and also polyreactive antibodies directed against apoptotic cells may cause ABMR[34].

The antibodies cause graft damage by endothelial cell injury mediated by the activation of complement. C4d is a split product of C4 activation and is often present on endothelial cells in ABMR. Sis *et al*[35]described that 60% of kidneys with high endothelial activation and injury transcripts (ENDATs) and chronic ABMR were C4d negative. A recent microarray study from Sellares *et al*[36] concluded that changes in ABMR-associated gene expression correlates with the presence of capillary lesions or of DSAs and may predict graft failure independently of C4d staining. Taken together these observations point to the low sensitivity of C4d for the diagnosis of ABMR and support the addition of novel biomarkers of capillary inflammation and endothelial injury, including natural killer (NK) cells and macrophages, for the diagnosis algorithm of ABMR[37,38]. This recommendation was officially incorporated into the new Banff 2013 diagnostic criteria for ABMR[39].

The 12th Banff conference on allograft pathology was held in Comandatuba, Brazil in August 2013. The conference led to the following conclusions in the field of ABMR in renal allograft: (1) For acute/active ABMR the following three features bust be present for diagnosis, histological evidence of acute tissue injury, evidence of current/recent antibody interaction with vascular endothelium, serologic evidence of DSAs; (2) For chronic/active ABMR the following three features must be present for diagnosis, morphologic evidence of chronic tissue injury, evidence of current/recent antibody interaction with vascular endothelium, serologic evidence of DSAs; and (3) C4d staining without rejection (often accommodation), must include, linear C4d staining in peritubular capillaries, no morphologic lesions by light microscopy and electronic microscopy, no acute cell-mediated rejection.

***New techniques involved in rejection diagnosis***

Bachelet *et al*[40]with a seminal work demonstrated that DSAs detection in kidney allograft biopsy eluates is a feasible method to predict the graft outcomes. Indeed, patients with intragraft DSAs displayed more severe ABMR pathology and worse outcome than patients with only DSAs in the serum. According to this work the intragraft DSA detection is a new test to dichotomize HLA antibodies into high and low injurious activity[41].

There are no doubts on the unmet medical need for improvement of diagnostic of renal injury to allow a more personalized therapeutic approach. Therefore, it is believed that the opportunity lies in new technologies such as molecular analysis, as messenger RNA (mRNA) and micro RNA (miRNA) expression from biopsies or even from blood or urine samples[42].

Two reports from the group of Edmonton in 2013 reported the results of molecular analyses of renal allograft biopsies[43, 44]. The first report aimed to develop a diagnostic test for the T and B cell-mediated rejection by bootstrapping from the pathology.

The main messages of this paper were: (1) A molecular scoring was developed for diagnosis of rejection; (2) A molecular classification is based on selected genes related to immune cells and their activation products; and (3) The study confirmed certain disagreements among pathologists in applying the golden standard histopathology. In two other studies[45, 46] the scoring assessed by the microarray test was validated by the INTERCOM study.

These papers revealed that a previously identified “acute kidney injury signal” early after transplantation was also present in the late kidney biopsies related to late T cell and ABMR, but not to fibrosis.

The multicenter Clinical Trials in Organ Transplantation 04 (CTOT-04) study was designed to investigate whether the urinary-cell mRNA levels encoding immune system proteins implicated in transplant rejection are diagnostic of acute rejection[47]. By logistic regression the authors correlated a three-gene signature of CD3ε mRNA, IP-10 mRNA, and 18S rRNA levels in urinary cells with allograft rejection. This study offers new insight into the possible use of non-invasive diagnostic and prognostic markers for the acute cellular rejection in kidney allograft.

**NEW INSIGHTS FOR PANCREAS AND ISLET TRANSPLANTATION**

***Transplant activity and graft survival***

Pancreas and islet cell transplantation (ICTx) confirmed to be the best treatment for diabetes mellitus type I (T1DM). According the OPTN/SRTR data, the number of pancreas transplants has decreased over the past years, most notably the numbers of pancreas after kidney (PAK) and pancreas transplant alone (PTA)[48]. Deceased donor pancreas donation rates have been declining since 2005 and the donation rate remains low. The outcomes of pancreas graft are better for simultaneous pancreas-kidney (SPK) transplantation. The challenges of pancreas transplant are reflected in the high rate of re-hospitalization, most occurring within the first six month post-transplant.

Very recent data[49] confirm the excellent long-term prognosis of SPK transplantation principally in recipients with functioning graft 1-year after transplantation. Patients who receive PTA or PAK grafts have shorter long-term graft survival[50]. Multiple strategies are aimed to be applied to improve immunologic surveillance and to obtain an early diagnosis of the graft rejection in patients receiving PTA.

An interesting study[51] documented an improved patient survival rate for recipients with diabetic end-stage renal disease receiving SPK than that receiving kidney transplant alone (KTA). ICTx remains a hot topic. The collaborative islet transplant registry (CITR) investigators[52] presented the results of 752 islet allograft recipients with optimal and improving insulin independence rate at 3 years.

***Pancreas transplantation for type 2 diabetes mellitus***

SPK is widely accepted as an optimal therapeutic option for patients with T1DM and end-stage renal disease, but the indication for patients with type 2 diabetes mellitus (T2DM) is still controversially discussed. Indeed, there is continued uncertainty as to whether to T2DM patients are appropriate pancreas transplant candidates. In an editorial of 2012 Cohen *et al*[53]reviewed the most recent experience with pancreas transplantation in T2DM.

Gruessner *et al*[54] summarized the united network for organ sharing (UNOS) and International Pancreas Transplant Registry (IPTR) and reported no differences in the outcomes of patients with T2DM versus T1DM. Orlando *et al*[55] also found equivalent outcomes, regardless of whether the patients were classified as having T1DM or T2DM. Sampaio *et al*[56] reviewing the UNOS database, reported similar results even if T2DM represented only from 4.1% to 7.4% of diabetic patients transplanted.

More recently, Margreiter *et al*[57] reported the outcomes of 21 T2DM recipients receiving SPK and 32 T2DM receiving KTA. Patient and kidney graft survival rates were significantly lower for patients with KTA. The multivariate analysis adjusted for donor and recipient age, body mass index and coronary risk factors, showed that the differences did not remain statistically significant. The authors concluded that, according to the selection criteria proposed by other groups[58], selecting T2DM with an acceptable coronary risk profile and ageing not more than 55 years, is useful to identify those patients that may have a benefit from SPK.

***ABMR in pancreas transplantation***

ABMR is a recently identified entity. In a recent published paper[59], risk factors for pancreas ABMR were PTA and race mismatch. The diagnosis should be actively sought using C4d staining and DSAs levels in patients with graft dysfunction.

Preliminary studies have been presented at the already mentioned 2013 Banff conference[39]. These studies described the potential association of rejection-related vascular lesions with ABMR. Other studies demonstrated that immunostaining can enhance the understanding of pancreas T cell mediated rejection (TCMR) and ABMR even if the accurate grade and type of rejection rests principally on the systematic evaluation of morphological features on routinely stained sections[60].

***Islet transplantation***

ICTx is a modality to treat selected diabetic patients. The “Edmonton Protocol” became a milestone by reporting sustained C-peptide production and high rates of insulin-independence after transplant in T1DM[61].

Long-term analysis of these results indicates that insulin-independence was not durable and most patients returned to moderate amounts of insulin approximately 5-years post-infusion[62]. The causes for this islet graft dysfunction are not completely understood, but are likely associated to several factors as the immune rejection, the autoimmunity or the chronic exposure to diabetogenic immunosuppressant[63].

In the last years relevant progress has occurred testing new immunosuppressant, testing novel devices to provide islets with a safer environments, as well as new transplant sites to overcome the limitations inherent to the current intraportal access[64-68]. The autoimmunity is a limiting factor to the success of ICTx. In a recent study Takita and coll[69]. documented an early loss of transplanted allergenic islets despite T cell depletion induction. The authors concluded that the T cell depletion with anti-inflammatory regimen can enhance engraftment and survival; however, autoimmune recurrence by islet auto antibodies, principally GAD65 may limit the results.

The revascularization of transplanted pancreatic islets and the role of the transplantation site is another important issue[70]. Indeed, pancreatic islets are highly vascularized, which is important for their ability to secrete insulin in response to changes in blood glucose. The islet isolation process interrupts the connections between the islet vasculature and the systemic circulation. As the revascularization of the ICTx is not immediate, allocating cells in proximity to a good vascular supply is essential. A recent study proved the impaired revascularization of pancreatic islets into the liver[71]. In addition, the portal vein after islets injection undergoes instant blood-mediated inflammatory rejection (IBMIR) which results in an early inflammatory reaction. Therefore, it is essential to avoid this by either identifying a transplant site with minimal interaction with blood or by protecting the vascular grafts from IBMIR[70].

Among other sites, recent studies documented good results with omentum and muscle. The peritoneum offers an unlimited space for transplanted islets and is an attractive site for concurrent use of encapsulated device to protect the islets. A recent study[72] suggests the potential for longevity of islets allocated in the peritoneal cavity. Muscle-skeletal sites offer several advantages. They are easy to access, offer substantial space in which to transplant cells and are highly vascularized making them a very useful area. In a recent study, mice islets were successfully transplanted intramuscularly and the authors concluded that the early hypoxia after transplantation could be overcome by co-implantation of polymerized hemoglobin[73].

Finally, the islet encapsulation has been the issue of a very recent review[74]. Islet encapsulation allows the protection of this tissue without the use of toxic medications and expanding the donor pool to include animal sources. Before the use of this therapy, there are still issues that need to be resolved as the materials to be used, the shapes and sizes of the capsules and the aspects of bioengineering.

**NEW INSIGHTS FOR LIVER**

***Transplant activity and liver graft survival***

According the OPTN/SRTR data, in United States the number of adults who registered on the liver transplant waiting list decreased for the first time since 2002. However, the median waiting time for active wait-listed adult candidates increased, as did the number of candidates removed from the list because they were too sick to undergo transplant[75]. Graft survival continues to improve, especially for donation after circulatory death livers.

Since the first liver transplantation, short-term survival has improved rapidly; however, long-term attrition rates have not changed similarly[76]. In 2013 the first publication of European single-center 20-year survival data have been published[77]. The 20-year patient and graft survival rate of 313 patients has been reported. The 20-year patient and graft survival rates were respectively 52.5% and 46.6%. These results were better than two other single center long-term survivals[78, 79] and also than the 20-year survival published by the European Liver Transplant Registry (ELTR)[80].

Impaired renal function and re-transplantation had significant impact on patient survival and recurrent diseases. Infections and de novo malignancies were the main cause of death. Much work is needed to combat recurrent disease and side effects of immunosuppressants.

The Japanese Liver Transplantation Society (JLTS) analyzed the outcomes of 2224 pediatric patients who underwent living donor liver transplantation[81]. No donor mortality related to transplant has been reported and the 10 and 20-year patient survival rates were 82.8% and 79.6%, respectively.

Primary disease impacts on the outcomes of liver transplantation (LTx). A recent analysis of OPTN/SRTR[82] documented an optimal short and long-term survival of LTx for primary biliary cirrhosis (PBC); similar good outcomes were reported for primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH) and for hepatitis B virus (HBV). The worst results (HR = 1.5-2.4) were reported for hepatitis C virus (HCV) and hepatocellular carcinoma (HCC).

More than one-third of listed potential liver recipients in many western and some Asian countries are infected with the HCV. Recurrence of infection with HCV after LTx is associated with accelerated graft loss and diminished patient survival[83]. Until recently, HCV treatment has been limited to the use of pegylated interferon alpha (Peg IFN) plus ribavirin. In 2012 two direct acting anti-viral drugs, boceprevir and telaprevir were licensed by FDA for the treatment of chronic genotype 1 HCV[84, 85]. The use of protease inhibitors (PI) based triple anti HCV therapy in LTx recipients, is complicated by the known pharmacokinetic effect of the PI on cytochrome P450[86]. Nevertheless, promising small series of HCV recipients treated by PI based triple therapy have been reported[87]. Future approaches rely on the possible use of prophylactic neutralizing monoclonal antibodies to HCV[88].

***Ischemia reperfusion injury***

IRI is a major cause of morbidity and mortality in LTx. After a transient ischemia, the restoration of blood flow is necessary to restore cellular function, but paradoxically the reperfusion can initiate a cascade of pathways that causes further cellular injury after prolonged ischemia[89].

The lack of oxygen in hepatocytes during ischemia causes adenosine 3 phosphate (ATP) depletion and alterations in H+, Na+ and Ca2+ homeostasis that activate hydrolytic enzymes and impair the volume regulation, leading to the swelling of sinusoidal endothelial cells (SECs) and Kupffer cells (KCs). This fact together with the imbalance between nitric oxide (NO) and endothelin production, contributes to the narrowing of the sinusoidal lumen and thus to microcirculatory dysfunction. The activation of KCs releases reactive oxygen species (ROS) and proinflammatory cytokines (TNF alpha and IL 1). Cytokines and chemokines promote neutrophil activation and subsequent release of ROS and proteases. In addition, IL 1 and TNF alpha activate CD4 T-lymphocytes which produce granulocyte-macrophage colony-stimulating factor, IFN gamma and TNF beta. Platelet-activating factor can prime neutrophils for superoxide generation[90].

Several studies in 2013 evaluated different molecules in attempt to attenuate the damage induced by IRI. The most important studies in this field have been extensively reviewed in the work of Akhtar and coll[91]. Attempt to protect IRI may involve several strategies and several pathways[92-95]. This issue will be described in the therapy chapter.

***DSA and acute and chronic liver rejection***

The issue of the impact of preformed DSAs on LTx has been a matter of discussion. Early clinical experience showed no differences in patient or graft survival rate[96-98] and DSAs were thought to be an integral part of tolerance development. Later studies documented that patients transplanted with a positive cross-match had an increased risk of early graft loss[99-101]. However, since consistent results are lacking, practice has not changed. In 2013, a study from Kaneku *et al*[102], documented that patients with LTx developing de novo DSAs after transplantation, had significantly lower patient and graft survival rates.

The 2013 Banff conference[39] stated that currently, recognized acute ABMR, occurs in small percentage of sensitized patients and that DSAs can be associated with more progressive fibrosis and an indolent progressive perivascular and subsinusoidal fibrosis. The conference concludes that high titer IgG3 recipients more often show adverse consequences, whereas exclusively not IgG3/IgG1 DSAs appear in some operationally tolerant recipients weaned from immunosuppression.

***New tools for rejection diagnosis***

Current liver biopsy is the most frequent used technique to evaluate allograft status and is the gold standard for the diagnosis of the acute rejection after orthotopic liver transplantation (OLT). As already described for the kidney, plasma microRNA is now revealing to be a potential biomarker for acute rejection after OLT[103,104].

**NEW INSIGHTS FOR HEART**

***Figures, characteristics and trends for heart transplantation***

According to the OPTN/SRTR data, in United States the number of heart transplants performed annually continues to increase gradually, and the number of adult candidates on the waiting list increased by 25% from 2004 to 2012[105]. Heart transplantation (HTx) appears to be more expensive than ventricular assist devices for managing the end-stage heart failure, but is more effective and likely more cost-effective.

By the end of 2013 the data of the Registry of the International Society for Heart and Lung Transplantation (ISHLT) have been published[106]. Cardiomiopathy in recent years has been the leading cause for HTx, followed by coronary artery disease (CAD). This trend has been particularly higher in Europe and the rest of the world than United States, reaching percentage of 57%-60%. Both recipient and donor age statistically increased, as well as the percentage of patients with pre-transplant panel reactive antibodies (PRA) in the sera > 10%.

In the recent years a highly significant number of patients bridged to transplantation with mechanical circulatory support (MCS) have been registered. Nevertheless, should be outlined that a better survival rate has been reported for patients not on mechanical support prior transplantation.

A progressive and significant increase of Kaplan Meier survival by ERA was reported except for the last two years. Congenital diseases as primary disease attained the best survival rate while re-transplants attained the worst. Importantly long-term freedom from cardiac allograft vasculopathy (CAV) was higher by ERA and by female gender. The causes of death were stable in the last year with prevalence of graft failure, followed by infections.

In 2013, the ISHLT Registry focused a peculiar study on the relevance of age. Interestingly in the recent years, the graft survival rate was not statistically influenced by recipient age, except 18-39 years compared to 60-69 years. On the contrary donor age had significant impact on the graft survival. CAD was the leading cause of HTx for patients aged 60-69 years (53%).

In the recent years an increase of both donor and recipient age has been registered. The most striking variation for elder patients has been observed as the percentage of patients bridged with MCS. By 2012 almost 40% of patients ageing 60-69 years were on MCS prior to transplantation, while only 15% of patients had similar support by 2006. Leading causes of death for patients ageing 60-69 years were graft failure and infections. The elder patients had also more malignancies and after 10 years only 50% of patients were free from malignancies.

***Mechanical circulatory support***

As aforementioned in recent years we observed an impressive advance in MCS devices and, overall, newer MCS devices are smaller and more reliable than the first generation of technological devices. Increasing number of reports conclude that in some cases of heart failure, the devices may be used not only as bridges to transplantation, but also as destination therapies[107]. A new device, the Heart Ware Ventricular Assist System is a miniaturized implantable continuous flow blood pump and in 332 patients in a pivotal bridge to transplant demonstrated a high 180-day survival rate[108]. This and other mechanical supports were examined in a recent paper[109] which led to the conclusion that patients with mechanical support, despite being older and less favorable recipients, spent more time in status 1A and had greater waitlist survival.

In a systematic review, Sutcliff *et al*[110] tried to evaluate the clinical effectiveness and cost effectiveness of last generation MCS as either bridge to transplant (BTT) or alternative to transplant (ATT). The authors concluded that MCS as BTT compared with medical management (MM) are effective but with higher cost-effectiveness ratio. MCS as ATT have a reduced cost, but cause reduced quality of life. Considering the wide use of MCS, with the intent to regularize its use, in 2013 ISHLT published the Guidelines for the use of MCS[111].

***Prediction of mortality and cardiac allocation score***

As a consequence of the aforementioned variables impacting on heart graft survival, several attempts have been made to evaluate the mortality prediction after heart transplantation. In 2013 the Index for Mortality Prediction after Cardiac Transplantation (IMPACT) score was validated using international data[112]. This study validated the use of the IMPACT score as a predictor of short- and long-term mortality after orthotopic heart transplantation (OHT).

Other scoring modalities, in addition to the IMPACT score, are the Heart Failure Survival Score (HFSS), the Seattle Heart Failure Model (SHFM) and the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). All these scores were evaluated in a Eurotransplant pilot studyfor predicting waiting list mortality among heart transplant candidates and among transplanted patients[113]. In non MCS patients all the scores provide accurate risk stratification. The authors conclude that further studies are needed to reveal whether these models should be considered the basis for a new heart allocation policy.

***ABMR in heart transplantation***

Previous studies have documented that the presence of de novo donor HLA specific antibodies after HTx is an independent predictor of poor survival[114]. Similarly the detection of Luminex positive DSA in pre-transplant serum is a negative predictor of mortality[115] and also IgM non HLA antibodies have been identified as a risk for early allograft failure[116].

Nevertheless in the last Banff Conference[39] it was observed that lacking of search for DSAs or C4d staining are limiting factors to identify ABMR in heart transplantation. While biopsies positive for C4d and C3d are strongly associated with DSAs and allograft dysfunction and represent true ABMR, biopsies only positive for C4d are mostly subclinical. On a morphologic basis, is not possible to designate the latter as accommodation versus subclinical ABMR. Moreover there is also uncertainty about the management of subclinical ABMR. To this end the American Heart Association will be publishing a scientific statement evaluating clinical and pathological evidence regarding ABMR.

The ISHLT working formulation for the standardization of nomenclature of ABMR in heart transplantation has published a consensus paper by the end of 2013[117]. As ISHLT itself recognizes is hard to date to make a definitive statement on this issue and there remain numerous challenges and unresolved clinical, immunologic and pathologic questions. Moreover, there is no hard evidence of a direct causality between ABMR and cardiac allograft vasculopathy (CAV), neither any systematic study of antibody-dependent cellular cytotoxicity (ADCC) as an alternative mechanism linking antibodies to CAV[39].

***Chronic cardiac allograft rejection: new insights***

Several papers in 2013 have treated new findings on chronic cardiac allograft rejection. A review by Costello *et al*[118] recognized that chronic rejection in the form of CAV is one of the major factors that affect the long-term graft and patient survival. Whereas multiple factors (hyperlipidemia, cytomegalovirus, baseline coronary artery disease) contribute to the development of CAV, immunologic mechanisms play the prevalent role.

Using the intravascular ultrasound (IVUS) to evaluate intimal thickening, some recent studies have validated the use of everolimus (EVR) with reduced-dose cyclosporine (CsA)[119,120]. These studies documented a similar efficacy of EVR with reduced-dose CsA to Mycophenolate Mofetil (MMF) with standard-dose CsA and a reduced intimal proliferation at 12 mo in de novo heart transplant recipients. However, these studies have been criticized[121] both because IVUS was made only in a subgroup of patients and because IVUS was performed only at 1 year post-transplant.

Finally, the technique of optical coherence tomography has been proposed to evaluate cardiac allograft vasculopathy[122]. This is a new technique to assess early morphologic changes, but its clinical predictive value remains to be determined.

**NEW INSIGHTS FOR LUNG**

***Figures, characteristics and trends for lung transplantation***

In United States lung transplants are increasingly used as treatment for the end-stage lung diseases. Lungs are allocated to adult and adolescent transplant candidates on the basis of age, geography, blood type compatibility and the Lung Allocation Score (LAS)[123]. The overall median waiting time in 2012 was 4 mo, and 65.3% of candidates underwent transplant within 1-year of listing. Both graft and patient survival rates have continued to improve; survival rates for recipients aged 6-11 years are better than those of younger recipients. Similarly as for the heart by the end of 2013 the data of the ISHLT Registry have been published also for the lung[124].

Obstructive pulmonary diseases (COPD), interstitial pulmonary fibrosis (IPF) and cystic fibrosis (CF) are among the most common causes of LuTx. COPD represents one of the most common indications for LuTx and accounts for one/third of all the procedures[125]. Worldwide a recent analysis of all the recipients reported that 23% had IPF and 3% pulmonary artery hypertension[126]. LuTx has become an excellent treatment option for patients with CF and bronchiectasis. In these patients survival is more favorable than that seen in patients with COPD and IPF[127].

In recent years there has been a significant increase of recipient’s age (24% ageing 60-65). As a consequence there was an increase of patients transplanted for COPD, for IPF and for re-transplantation. Though the patients with COPD, IPF and re-transplant have the worst survival, an increase of Kaplan Meier survival by ERA was registered. Recently has been reported an increase of bilateral/double LuTx with respect to single LuTx for all the primary diseases. As double LuTx is associated with an improved graft survival rate for any disease, this could be the cause for the improved survival rate observed in recent years.

Among the side consequences of lung transplantation, both a reduction in renal dysfunction and an increase of hyperlipidemia and diabetes has been registered and probably this fact is related to modification in the dose and type of immunosuppressant[124].

***Donor selection and extended criteria donors***

The scarcity of suitable donor organs limits lung transplantation[128]. To overcome this problem, recently there was an increased interest towards an expanded donor pool associated with the techniques aimed to evaluate an improve donor lungs as the availability of *ex vivo* lung perfusion (EVLP). The utilization rate of these lungs changed from less than 15% to 50%. It is now quite clear that many of the historical factors used to define a lung as “Extended” do not actually produces significantly worse outcomes.

In a review of the UNOS database[129], the outcomes after LuTx using donors aged 55 to 64 years, were similar to those observed with standard donors. In this review only the donors aged more than 65 years were associated with the decreased intermediate-term survival. In Eurotransplant in 2013 the Hannover center reported its results utilizing lungs turned down for donor-related medical reasons by 3 centers. The authors obtained excellent graft survival similar to the standard lungs and concluded that the rescue allocation donor lungs may be used safely and therefore salvaged for the donor pool[130].

***New findings on recipients and LAS***

The relevance of size-matching has been evaluated in an extensive study based on evidence-based reviews[131]. Unfortunately the authors conclude that the evidence base that informs the decisions regarding lung size mismatching is limited and composed primarily of small studies with heterogeneous groups of patients.

Currently data are lacking to give the surgeons robust guidelines to conduct decision making for size matching of donors and recipients. Among the pre-transplant variables that affect the survival after LuTx, markers of nutritional status are associated with poorer recipient survival. A recent paper[132] examined several variables associated with the nutrition, including body mass index (BMI), body surface area, albumin levels, total proteins and immunoglobulins. Although no nutritional variables were found to be associated with major post-operative complications or infections, a low serum albumin (< 3 mg/dL) was associated with increased risk of death. Even if the results of this study differ slightly from others studies[133]; the body of literature to date suggests that the nutritional status may affect post-transplant outcomes.

The LAS was developed in 2005 to reduce the mortality on the waiting list, to prioritize candidates basing on urgency, to minimize the role of geography and to maximize the transplant benefit. In prioritizing patients with the most urgent status, a new controversy has come into the forefront: whether or not the increased number of critically ill recipients maximizes the transplant benefit. Despite the controversy, the LAS system is an improvement compared with the traditional first-come, first-served system and it has been adopted by UNOS and Eurotransplant[134]. A recent review of the UNOS data[135] concluded that social disparities in lung transplantation have decreased with the implementation of LAS; however, gender disparities (in favor of men) may have actually increased in the LAS ERA.

***Primary graft dysfunction, ABMR and chronic allograft dysfunction***

Primary graft dysfunction (PGD) is a syndrome encompassing a spectrum of mild to severe lung injury that occurs within the 72 h after LuTx. In addition, PGD has a significant impact on the short and long-term outcomes[136].

The pathogenesis of PGD is complex and influenced by donor, recipient, technical factors and by different combinations of all the above. PGD is driven by an inflammatory response as well as by immunological (both innate and cell mediated) processes[137]. Several strategies have been investigated to prevent and treat PGD[138]. These strategies will be discussed in the therapy chapter.

Allograft rejection is a major cause of a limited survival rate in LuTx. Moreover, the acute rejection represents the principal risk factor for chronic rejection[139]. Acute cellular rejection (ACR) is defined as a perivascular or peribronchiolar lymphocytic infiltrates primarily diagnosed by bronchoscopic transbronchial biopsies[140]. ACR involves several T-cell subtypes and several cytokines.

Data suggest a correlation between acute rejection and effector memory T cells in LuTx and the measurement of peripheral blood CD8+ effector memory T-cells before LuTx may define the patients at high risk for ACR[141].

The study of Krustrup *et al*[142] documented the association between the distribution of Tregs in the transbronchial biopsies and the level of FoxP3 mRNA in the bronchoalveolar lung fluid (BALF). This indicates that Tregs may play a role in the cellular processes that affect ACR and that looking for FoxP3 mRNA in BALF is a reliable non-invasive method for evaluating the number of Tregs in lung tissue.

Higher values of CXCL10 (IP-10) in BALF are associated with ACR in LuTx suggesting a potential mechanistic role in the pathogenesis of ACR[143]. These results suggest that therapeutic strategies to inhibit CXCL10 (IP-10) and/or its cognate receptor (CXCR3) warrant investigations to prevent and/or treat the ACR in LuTx.

Some retrospective studies conducted and published in 2013 highlighted the relevance of ABMR in LuTx. In one study[144] a clear association between DSAs, ABMR, ACR, bronchiolitis obliterans syndrome (BOS) has been documented. Another study[145] identified ABMR in 21 recipients basing on the presence of HLA-DSAs, the histological evidence of acute lung injury, C4d deposition and clinical allograft dysfunction. In this study the majority of patients who recovered from ABMR, developed chronic lung allograft dysfunction (CLAD) during the follow-up.

Due to the relevance of the syndrome, the Pathology Council of the ISHLT elaborated the Consensus points for pathologic diagnosis of pulmonary ABMR[146]. The conclusions were: (1) The diagnosis of pulmonary ABMR requires a multidisciplinary approach that includes the presence of clinical allograft dysfunction, circulating DSAs and pathologic findings; (2) The histopathology findings in ABMR are non-specific patterns of injury that can be seen also in disorders such as severe ACR, infection, graft preservation injury and drug reaction; and (3) Positive capillary C4d staining should be always reported.

The last Banff conference[39] reviewed the Pathology Council survey and added that the early detection of DSAs following LuTx and the systematic monitoring with sensitive solid-phase platforms are recommended[147]. The overall conclusions revealed that to date survival is poor after ABMR but may improve with the rapid clearance of the antibodies[145].

Important unanswered questions include: (1) How to grade graft dysfunction; (2) What constitutes a significant mean fluorescent intensity of DSAs; (3) How to manage the patient in whom there is discordance between the criteria enumerated; and (4) What’s about the non-HLA targets, principally because, according many authors, the BOS is the result of humoral response against non-HLA molecules[148].

CLAD continues to be the major limitation to long-term survival[149]. Its pathogenesis is complex and involves both alloimmune and non-alloimmune pathways. In particular, acute damage to the allograft, including episodes of acute rejection, PGD, cytomegalovirus (CMV), pneumonitis, gastro esophageal reflux and early and late new-onset diffuse alveolar damage have all been shown to increase the risk of CLAD[150].

BOS, characterized by obstructive physiologic changes, is the conventional form of CLAD. Increasing evidence, however suggests that CLAD is a heterogeneous condition and that BOS is not the only form of CLAD. While BOS itself has been recently redefined as neutrophilic reversible allograft dysfunction (NRAD)[151], Sato *et al*[152,153] recently identified a type of CLAD who showed restrictive physiology and peripheral lung fibrosis and named this condition “restrictive allograft syndrome” (RAS). The prognosis of RAS is poor and more severe than that of NRAD.

As already mentioned the pathogenesis is multi-factorial and recently has been documented that acute rejection, lymphocytic bronchiolitis, colonization with Pseudomonas, infection and BALF eosinophilia and neutrophilia are risk factors for both RAS and NRAD[154]. Moreover, immunologic factors as complement activation[155] and the defensins have been implicated in the pathogenesis of CLAD[156].

**NEW INSIGHTS ON IMMUNOSUPPRESSIVE THERAPIES IN SOLID ORGAN TRANSPLANTATION**

This chapter may be divided into two paragraphs: (1) Old drugs recently revised and used in new strategies; and (2) New drugs recently introduced on the market or still waiting for their approval.

***Old drugs recently revised and used in new strategies***

The concept that the chronic loose of renal function after kidney transplantation (KTx) should be ascribed to chronic renal calcineurine inhibitors (CNIs) nephrotoxicity, led to a number of trials attempting to avoid or withdraw CNIs from the maintenance immunosuppression therapy.

With the exception of few trials all these attempts documented that to date is not yet the time to give up with CNIs[157]. Moreover, in 2013 a meta-analysis[158] has not documented a favorable effect of CNIs reduction on kidney function in HTx.

Many trials of CNIs reduction have been made thanks to the use of mammalian target of rapamycin inhibitors (mTORIs), a class of drugs devoid of CNIs side-effects. Overall an analysis of 139370 United States kidney transplant recipients documented that the complete substitution of CNIs with mTORIs was associated to a greater risk of allograft failure and death[159].

The use of mTORIs in LTx led to contradictory results. In a phase II prospective randomized trial[160] the use of sirolimus with reduced dose of tacrolimus (TAC) in the de novo liver transplant recipients was associated with higher rates of graft loss, deaths and sepsis when compared to the use of the conventional dose of TAC.

In the recent H2304 trial[161,162] liver transplant patients randomized to EVR with TAC elimination showed strikingly good renal function at 2-year post-transplant, but this treatment group was terminated due to a higher rate of acute rejections. However, there was no significant difference between the EVR and reduced TAC *vs* TAC control group[163]. The study Preservation of Renal function in liver Transplant recipients with Certican Therapy (PROTECT)[164] documented that an EVR-based CNI-free immunosuppression is feasible following LTx and the patients benefit from sustained preservation of renal function when compared to patients on CNIs, for at least three years.

The discrepancies between the results of H2304 and PROTECT studies could be explained by the use of Il-2 receptor antibody only in the latter study and in the abrupt TAC withdrawal in the former.

The contradictions in the use of mTORIs in LTx have been examined in an editorial of Lewitsky *et al*[165]. Probably like any other drug with a narrow therapeutic window, mTORIs must be used in the right amount, right time period and right patient. Right amount is without a loading dose and targeting moderate trough levels. Right time is neither too early nor too late after LTx. The right patient is the one who is at high risk to develop nephrotoxicity.

Several studies document the attenuation of cardiac allograft vasculopathy by mTORIs. A study from Matsuo *et al*[166] documented the usefulness of sirolimus in the case of early initiation. As aforementioned, the recent most important contributions in this field are the Eisen[119] and Kobashigawa[120] studies.

They documented the efficacy of EVR with reduced-dose CsA, similar to MMF + standard dose CsA. Patients treated by EVR had reduced intima proliferation. Recently the use of mTORIs in the treatment of lung transplant recipients is an area of active investigation[167,168]. Newer researches involving the use mTORIs or antimetabolites have been made in the treatment and prevention of BOS[169,170]. In a recent review[171], Borro highlights that one of the advantages in LuTx is the administration of the treatments via the inhalator route.

A randomized, prospective study of inhalator CsA *vs* placebo documented significant improvements concerning survival and BOS free interval[172]. Inhalator corticosteroids have been suggested in the lymphocytic bronchiolitis, based on the possible reduction of the airway inflammatory markers[173].

Immune modulating and beneficial effect in LuTx have been documented for the statins and Azithromycin. Concerning statins, some groups have considered adding such treatment on a systematic basis in the patients with suspected or confirmed BOS[174]. Principally in patients with an increased bronchoalveolar lavage neutrophilia, azithromycin could prevent BOS, most likely through its interactions with the innate immune system[175].

The finding of the relevance of DSAs in determining ABMR and reduced graft function for any transplanted organ led to search for new strategies in organ immunosupppression. A systematic review[176] on the induction therapy in HTx concluded that acute rejection might be reduced by IL-2R antibodies compared with no induction and by the antithymocyte globulin (ATG) compared with IL-2R antibodies. Similarly, the depleting antibody induction has become the mainstay of immunosuppression in pancreas TX[177].

In KTx the use of ATG is associated with a significant reduction of DSAs and ABMR[178]. The Alemtuzumab induction therapy obtains similarly good results in a systematic review[179]. Further induction trials in the attempt to prevent ABMR with rituximab are ongoing, including the Rituximab Induction in Renal Tx (ReMIND) trial (Clinical-Trials.gov number NCT01095172)[180,181]. No result has been obtained with Rituximab in the treatment of ABMR as reported from a phase III multicenter, randomized, placebo-controlled trial (RITUX ERAH)[182].

***New drugs recently introduced in the market or still waiting for approval***

**Prevention and treatment of ABMR:** Eculizumab, the humanized anti C5 antibody is among the new drugs recently used in the prevention of the ABMR in KTx. Its efficacy was recently assessed in one study[183]. There is an ongoing, multicenter, international, randomized trial testing the role of eculizumab that may clarify its utility (NCT00670774)[184].

Limited clinical trial evidence suggests that the proteasome inhibitor Bortezomib may be useful to treat the ABMR following KTx[185]. Agents targeting the B activating factors belonging to the TNF Family (BAFF) pathway which co-stimulates B cell survival and expansion are also in the clinical development as atacicept and belimumab[186].

A further possibility in the field of ABMR is complement inhibition by C1-esterase inhibitors. A trial studying the safety and tolerability of the C1 inhibitor therapy in the prevention of the acute rejection is now ongoing (Clinical Trials gov NCT01134510).

**New drugs in KTx:** Belatacept, a fusion receptor protein that blocks the co-stimulation pathway CD80/CD86-CD28, was recently approved for the prevention of acute rejection in KTx. In 2013 two papers reported the results at 5 years of immunosuppression with belatacept + MMF and steroids respect to standard CsA maintenance immunosuppression[187,188]. Continued treatment with belatacept was associated with a consistent safety profile and sustained improvement in renal function *vs* CsA overtime.

In a smaller study Kirk *et al*[189] documented the feasibility of an immunosuppressive therapy in KTx with belatacept only, without maintenance steroids or CNIs after alemtuzumab induction. Another co-stimulation pathway is the CD40/CD40L pathway. Humanized anti CD40 antibodies prevented the acute rejection and prolonged the renal graft in non-human primates. In addition, these anti-CD40 antibodies appear safe and effective as maintenance immunosuppressive therapies[190,191]. To date 5 monoclonal antibodies directed against CD40 have been studied for different diseases including KTx (ClinicalTrials.gov NCT01780844).

Alefacept is a recombinant LFA3/IgG1 fusion protein that reduces the number of memory T cells. After its successful use in psoriasis, a recent study evaluated the efficacy of alefacept when combined with TAC, MMF and steroids in renal transplant patients[192]. 6-month efficacy, safety and tolerability were similar to control group, but the trial was too short to draw conclusions.

Janus kinase (JAKs), are a cytoplasmic tyrosin kinases that participate in the signaling of a broad range of cell surface receptors. JAK3 inhibition by tofacitinib in KTx trials in humans[193,194] have demonstrated tofacitinib to be non inferior to CsA for rejection rates and graft survival, however there was a trend towards more infections.

Sotrastaurin(AEB071) is a small molecular weight immunosuppressant that blocks the early T cell activation through selective inhibition of protein kinase C, crucial for IL-2 and interferon gamma production. In a phase II trial[195] sotrastaurin at a dose of at least 200 mg/d + reduced TAC had comparable efficacy to mycophenolic acid (MPA) in prevention of rejection. In another phase II study[196] sotrastaurin + everolimus compared to CsA + EVR had higher efficacy rates failure.

**New drugs in pancreas Tx and ICTx:** In pancreas Tx, after induction therapy the most widely used maintenance protocols are based on TAC and MMF with steroid withdrawal[197]. Considering the recent documented negative impact of DSAs on pancreas Tx, whether promising novel agents such as sotrastaurin, tofacitinib, belatacept, bortezomib or eculizumab will prove to be beneficial for pancreas Tx requires further investigations.

A long-term insulin-independence after ICTx was documented in 10 patients adding efalizumab or belatacept to the standard immunosuppression[64]. In another study[65] efalizumab was compared to belatacept and has been documented that efalizumab increases percentages of the circulating Tregs and profoundly suppresses T-cell reactivity, thus promoting the transplantation tolerance.

Combining anti-inflammatory biologics to maintenance immunosuppression has led to improved success rate. Naziruddin and coll[66], adding etanercept (TNF alpha antagonist) to immunosuppression obtained protection from inflammatory reaction during the peritransplant period. The same authors obtained an even better protection adding Anakinra (IL-1 beta blocker) to Etanercept[66]. Another group obtained excellent results adding Reparixin (CXCL8 inhibitor) to the immunosuppressive therapy[67, 68].

The stabilization of Glucagon-Like-Peptide-1 (GLP-1) by inhibiting Dipeptidyl Peptidase IV by sitagliptin increases beta cell mass by modulating vascularization[198]. To date two official trials are ongoing on the effect of sitagliptin (NCT00853944 and NCT01186562).

**New drugs in LTx:** In liver transplantation new drugs have been principally used to protect the IRI. Attempt to protect the IRI may involve several strategies and several pathways[92-95]. Elias-Miro and coll[92] evaluated antioxidant strategies to reduce the oxidative stress. The positive Pentoxifylline effect seems to be related to the inhibition of TNF alpha according Genoves and coll[93].

Tiriveedhi and coll[94] found a protective effect of Bortezomib on IRI. This proteosoma inhibitor effectively attenuates the IRI by inhibiting the matrix metalloproteinase (MMP) and the chitinase 3-like 1 (YLK-40) both involved in the extracellular matrix deposition and fibrosis principally in steatotic livers. The complement pathway is also involved in the IRI and a recent and promising study in the mice[95] documented that the C1-esterase inhibitor administration attenuates the liver injury compared to controls.

**New drugs in LuTx:** New drugs in the field of LuTx are represented by pirfenidone and the C1 esterase inhibitor. Pirfenidone, a small synthetic non peptide molecule demonstrated a potent antifibrotic effect by inhibiting the transforming growth factor beta (TGF beta) and TNF alpha, important mediators of fibrosis and inflammation. Its usefulness has been principally suggested in the lung transplant patients with RAS[199].

Over the last few years, the development of innovative techniques such as EVLP or the refinement in the artificial support methods as Extracorporeal Membrane Oxygenations (ECMO) also contributed to treat and redefine the outcomes of patients with PGD. A very recent study by Sommer and coll.[138] reported a trial with C1-esterase- inhibitor in patients affected by severe PGD. The one year survival was significantly higher than that of not treated patients.

**NEW INSIGHTS ON TRANSPLANT TOLERANCE**

One of the hallmarks of the adaptive immune system is its ability to recognize a vast number of different antigens. This ability is a consequence of the large lymphocyte repertoire, in which each cell has a different antigen receptor generated by the process of somatic recombination. This process is able to produce an estimate of 1015 different lymphocyte clones, each with a different antigen receptor that can hypothetically recognize any naturally occurring structure[200]. Since the somatic recombination is a random process, it generates T cell clones that can recognize self-structures or self-peptides (auto antigens). The mechanism used by the immune system in order to avoid a possible harmful immune response against an individual’s own cells and tissues, is known as the immune tolerance and can be classified into central and peripheral tolerance.

Immune tolerance in transplantation is defined as a specific absence of a destructive immune response to a transplanted tissue without immunosuppression. Operative criteria are the complete withdrawal of immunosuppression followed by no evidence for rejection for the transplanted organ for over one year. In humans is characterized by specific *in vitro* non-responsiveness to the donor.

Induction of tolerance differs according the transplanted organ. Indeed, although up to 20% of liver transplant recipients may be successfully withdrawn from immunosuppression[201]; operational tolerance to renal allograft appears to be much less frequent. In a recent review, Ruiz *et al*[202] reviewed the new strategies to induce the long-term acceptance to organ transplantation. These include: (1) Mixed chimerism as a strategy to induce allograft tolerance; (2) Dendritic cells and Regulatory Macrophages; (3) Exosomes and Phagosomes as tools for alloantigen delivery; (4) Apoptotic cells; (5) Regulatory T cells; and (6) Mesenchimal Stromal/Stem cells.

In the recent American Society of Transplantation (AST) Cutting Edge of Transplantation meeting, held in Arizona (US) February 13-15th 2014, the best approaches to induce renal allograft tolerance have been reviewed. They are principally two: (1) Tolerance through induction of durable chimerism. In HLA disparate patients the protocols to date principally used are the Massachusetts General Hospital and the Northwestern University protocols; and (2) Immunomodulation through use of donor hematopoietic stem cells, as the Northwestern University protocol.

Mixed chimerism is defined as the coexistence of donor and recipient hematopoietic cells after allogeneic bone marrow transplantation (BMT). To be considered mixed chimerism, donor cells in the blood must represent more than 1% of the total cells. To induce a state of mixed chimerism, it is necessary to perform a conditioning treatment in order to allow the donor bone marrow acceptance. Currently used mixed chimerism protocols induce robust donor-specific tolerance and allow long-term acceptance of fully mismatched skin grafts in murine models[203].

Recently Kawai *et al*[204] reported the results of a study of combined kidney and bone marrow transplantation without maintenance immunosuppression. The conditioning regimen consisted in cyclophosphamide, thymic irradiation, antiCD20 monoclonal antibody and an 8 to 14 mo course of CNIs.

The major problems encountered with these protocols have been “the engraftment syndrome” which causes transient renal dysfunction[205] and the occurrence of low levels of DSAs after discontinuation of immunosuppression. To overcome the engraftment syndrome, the authors have considered the use of low-dose total-body irradiation rather than cyclophosfamide as preconditioning treatment. DSAs occurrence caused an increase of anti CD20 administration.

As myeloablative conditioning is not ethically accepted due to the high risk involved in this type of conditioning, non myeloablative conditioning has emerged as an alternative to induce tolerance through mixed chimerism. Using a simultaneous bone marrow and kidney transplantation and a preconditioning protocol consisting in the co-stimulatory blockade with anti CD154 antibody, Kawai *et al*[206] and Wekerle *et al*[207] achieved the establishment of mixed chimerism in non-human primates. Later on, Kawai *et al*[208] reported tolerance induction using pharmacological immunosuppression and thymic irradiation. The main obstacle remains the presence of the memory T cells that can cross-react with alloantigens[209].

Other immunomodulatory cells with a high potential in future therapies in transplantation are hematopoietic mesenchimal stem cells (MSCs). It is well known that bone-marrow derived MSCs have the capacity to migrate to inflammatory sites and regulate the function of most immune cells through direct contact and/or by cytokine secretion[210].

Leventhal *et al*[211] developed an approach using a bioengineered mobilized cellular product enriched for hematopoietic stem cells (HSC) and tolerogenic CD8 positive/T cell receptor (TCR) - graft facilitating cells (FCs), combined with non-myeloablative conditioning. This allows the engraftment, a durable chimerism, and the tolerance induction in highly mismatched related and unrelated donor-recipient pairs.

The same author[212] reported in 2013 an intermediate-term follow up of this phase II trial. All 20 patients demonstrated donor specific hypo-responsiveness and were weaned from full-dose immunosuppression. Complete immunosuppression withdrawal at 1 year was successful with durable chimerism in the majority of patients. No graft versus host disease or engraftment syndrome has been reported. In all the cited studies a predictive biomarker for success versus failure in weaning immunosuppression has not been reliably identified and validated so as to be used as a tool to discontinue immunosuppression.

Leventhal *et al*[213] documented that durable chimerism predicts the outcome. Moreover, the immune/inflammatory gene expression in the peripheral blood and urine were differentially down regulated between tolerant and non tolerant recipients. As aforementioned memory T cells (Tm) represent a major barrier for immunosuppression and tolerance induction after solid organ transplantation. Taking into consideration the critical role of the intrinsic apoptosis pathway in the generation and maintenance of Tm, Cippà *et al*[214] developed a new concept to deplete alloreactive Tm by targeting B Cell Lymphoma-2 (Bcl-2) proteins. The small-molecule Bcl-2/Bcl-XL inhibit ABT-737 efficiently induced apoptosis in alloreactive Tm *in vitro* and *in vivo* and prolonged skin graft survival in sensitized mice. Since Bcl-2 inhibitors yielded encouraging safety results in cancer trials, this novel approach might represent a substantial advance to prevent the allograft rejection and induce tolerance in sensitized recipients.

The mechanisms above mentioned to induce tolerance are almost the same for the liver, even if the liver has particular tolerogenic properties that allow its being spontaneously acceptable in some animal species. The liver structure is considered to favor a tolerogenic environment. Indeed several studies demonstrated that the liver capacity to induce tolerance partly results from the in situ T-cell activation. The hepatocytes, as non-professional antigen presenting cells (APCs), may play key roles in regulating the immune responses and facilitating tolerance induction[215]. Warren *et al*[216] documented that the intrahepatic lymphocytes and the circulating naïve CD8+ cells could interact with the hepatocytes by means of cytoplasmic extensions capable of going through the liver sinusoidal endothelial cells fenestrations. This local activation of T cells by the hepatocytes provides the latter with a significant role as APCs and induces tolerance development in the liver[217]. The peripheral tolerance mechanisms also play a role in liver graft spontaneous tolerance. As for kidney, also for the liver the most significant mechanism in the tolerance induction is the chimerism[218]. In humans BMT-induced mixed chimerism has been shown to confer the acceptance of donor liver allograft without long-term immunosuppression. However, recipients must be able to withstand the conditioning regimens that allow donor stem cell to engraft.

**NEW INSIGHTS ON MAJOR COMPLICATIONS IN TRANSPLANTED PATIENTS: INFECTIONS AND CANCERS**

***Infections***

Infections post solid organ transplantation (SOT) is one of the more important complications. In 2013 many papers have been published on this topic. Among these, the most relevant, in our opinion are: (1) The publication of the third Edition of the American Society of Transplantation on Infectious Disease Guidelines[219]; (2) the publication of the Public Health Service (PHS) Guidelines for Preventing Transmission of Human Immunodeficiency Virus (HIV), HBV and HCV through organ transplantation[220]; (3) the International Consensus Guidelines on the Management of CMV in SOT[221]; and (4) an Overview on CMV and the Herpes Viruses in transplantation[222] .

Two main factors increase the risk for transplanted patients for infections following transplantation: (1) Risk related to the continuous expanding pool of marginal donors; and (2) Risk related to the requirement to increase immune suppression to treat rejection after SOT. In particular the use of antilymphocyte preparations and many of an increasing diverse list of biologic agents have been associated with an enhanced risk of infection[223].

Overall the risk factors that predisposes to infections in the recipients of SOT may be categorized as being present before transplant within the recipient and those secondary to intraoperative and post-transplant events[224]. Organ transplant recipients are at risk of acquiring pathogens from donors with active or latent infections at the time of the procurement. Examples of pathogens associated with expected donor-derived infections include CMV, Epstein Barr Virus (EBV) and Toxoplasma. Of greater concern is the development of unexpected donor-derived infections from a growing number of pathogens, including Mycobacterium tubercolosis, Histoplasma, West Nile virus, HBV, HCV and HIV.

Although OPTN policy requires that all potential deceased organ donors are screened for HIV, HBV and HCV by serology, no current policy requires the use of nuclear molecular acid testing (NAT) for donor screening. In 2013 an electronic survey was sent to 58 Organ Procurement Organizations (OPOs) in the United States to assess the current screening practices[225]. All OPOs performed the required serology screening, even if only 52% performed NAT for HIV and HCV. Moreover, respect to a previous survey made in 2008[226], the number of OPOs performing NAT has increased and more OPOs are now testing all donors.

In 2013 the PHS published new Guidelines for reducing HIV, HBV and HCV transmission through organ transplantation[220]. These Guidelines superseded the 1994 PHS Guidelines[227]. Most significant changes are: (1) Expanding the Guideline to include HBV and HCV in addition to HIV; (2) Using factors known to be associated with an increased likelihood of recent HIV, HBV or HCV infection; and (3) Limiting the focus to organs and blood vessel conduit recovered for organ transplantation because the FDA implemented more comprehensive regulations for human cell and tissue products[228].

These guidelines include 34 recommendations on risk assessment of living and deceased donors; informed consent discussion with transplant candidates; testing of recipients’ pre and post transplant, collection and/or storage of donor and recipient specimens and tracking and reporting of HIV, HBV and HCV.

***Studies on specific pathogens***

The human BK polyomavirus is the major cause of polyomavirus-associated nephropathy (PyVAN). Because effective antiviral therapies are lacking, screening kidney transplant patients for BKV replication in urine and blood has become the key recommendation to guide the reduction of immunosuppression in patients with BKV viremia. Retransplantation after PyVAN is largely successful, but requires close monitoring for recurrent BK viremia[229].

Sood *et al*[230] evaluated the relationship of pre-transplantation BK virus-specific donor and recipient serostatus to post-transplant BKV infection. Overall infection was highest in the D+R- group and lowest in the D-R-group. BKV serostatus may be used to risk stratify patients for post-transplantation infection.

CMV remains one of the most common complications affecting SOT, with significant morbidity and occasional mortality. In addition to the direct effects of CMV infection and disease, there are indirect effects, both general and transplant specific, which may significantly impact the outcomes.

An international panel of experts was convened by late 2012 to revise and expand evidence and expert opinion-based consensus guidelines. The reports of such recommendations have been published in 2013[221]. Viral culture of blood or urine has a very limited role for the diagnosis of the disease. Histology/immune-histochemistry is the preferred method for diagnosis of tissue-invasive disease. Quantitative nucleic acid amplification testing (QNAT) is preferred for diagnosis, decision regarding pre-emptive therapy and monitoring response to therapy. If QNAT is not available, antigenemia is an acceptable alternative.

Both universal prophylaxis and pre-emptive strategies are viable approaches for the prevention of CMV disease. For D+R- the use of either prophylaxis or pre-emptive therapy after kidney and liver transplant are recommended. For D+R- the use of prophylaxis over pre-emptive therapy after heart and lung Tx is recommended. When a pre-emptive therapy strategy is used, it is recommended that the centers develop and validate their local protocol[231]. For non-severe CMV disease, Valganciclovir or intravenous Ganciclovir are recommended as first line treatment, while dose reduction of immunosuppressive therapy should be considered in severe CMV disease.

CMV vaccines are in preclinical, phase I and phase II trials[232,233]. The primary goal of a CMV vaccine should be to prevent or to modulate CMV replication and/or CMV disease. Herpes viruses infect most animal species. Infections due to the eight human herpes viruses (HHV) are exacerbated by immunosuppression in SOT. The special features of the herpes virus life cycle include the ability to establish latent, non-productive infection and the life-long capacity for reactivation to productive lytic infection. Interactions between the latent virus and the immune system determine the frequency and severity of symptomatic infection. In an overview Fishmann[222] reports how the immunologic and cellular effects of herpes virus infections contribute to risk for the opportunistic infections and the graft reactions. Among the most important advances in transplantation are laboratory assays for the diagnosis and monitoring of herpes virus infections and antiviral agents with improved efficacy in the prophylaxis and therapy.

HCV infection is common in SOT recipients and is a significant cause of morbidity and mortality after transplantation. The severity of HCV infection in liver transplantation has been already discussed in the liver chapter. Carbone *et al*[234] reviewed the extent of the problem in donors, kidney, heart and lung transplant candidates.

In HCV-infected kidney allograft recipient, the progression of fibrosis should be evaluated serially. Transplantation of kidneys from HCV positive donors should be restricted to HCV positive recipients. HCV antiviral therapy should be considered for all HCV-RNA positive kidney transplant candidates. The impact of HCV infection on survival in heart and lung transplantation is unclear but even assuming a worse survival in those receiving HCV-infected organs, it has not been evaluated whether they do better or worse than those remaining on the waiting list.

***Cancers***

Malignancies after SOT are divided into three chapters: donor transmission of cancer, recipients with prior cancer and general epidemiology of cancers after SOT.

**Donor transmission of cancers:** Xiao *et al*[235] reviewed all case reports, case series and registry studies that described the outcomes of the kidney transplant recipients with donor cancer transmission published up to December 2012. The most common transmitted cancer types were renal cancer, followed by melanoma, lymphoma and lung cancer. Overall the risk of donor transmission of cancer appears low, but there is a high likelihood of reporting bias. The findings of this review support the current recommendation for rejecting organs from donors with a previous history of melanoma and lung cancer, but suggest that the use of donor kidneys with a history of small, incidental renal cell cancer may be reasonable.

At the 2013 American Transplant Congress (ATC), Desai *et al*[236]analyzed data from 30000 recipients of SOT from more than 14000 donors in the National Transplant Registry (NTR) in the United Kingdom (UK) to determine whether the risk of cancer transmission from organ donors could be eliminated.They found a very low rate of donor-origin cancer: only 0.6%. The risk of cancer transmission cannot be eliminated because the presence of cancer was not known at donation. This finding is useful to obtain an informed consent for prospective recipients, but in transplants other than kidney and pancreas, the benefits should be planned against the risk of remaining on the waiting list.

In another study the same group looked at donor transmission in a different way, linking donor data to the cancer registries, to determine the risk for donor transmission to the recipients analyzing more than 17000 donors[237,238]. More than 200 (about 1.5%) had a cancer history. Although 61 of these donors were at high risk for transmission, none transmitted their cancer to any of the recipients. These data raise the question about whether we are being too strict and losing potential donors. To put this in context, the death rate on the waiting list is 5% to 15% per year compared with this very low rate of donor transmission of cancer.

At 2013 ATC, Engels *et al*analyzed data from the SOT registry in the US to link donor organs to 15 cancer registries[239,240] .They concluded that recipients of donors with the cancer did not have significantly increased incidence of cancer compared with the recipients whose donors did not have cancer.

**Risk of recurrence of preexisting cancer in organ recipients:** Again Desai *et al*[241] analyzed data from NTR in UK on the issue of the recurrence of a preexisting cancer in an organ transplant recipient. They identified 64 (1.32%) recipients with a history of cancer diagnosed before organ transplantation.

5 recipients developed cancer recurrence and the rate of recurrence within 10 years was 11.9%. This study is interesting because data on this topic are sparse, and it’s increasingly become a problem for nephrologists as the ESRD population ages and the burden of co morbidity in KTx candidates is increasing. Although this is a small cohort, the data are useful because this is one of the only contemporary studies of cancer recurrence risk in SOT recipients.

**De novo post-transplant malignancies**

De novo post-transplant malignancies (PTM) are a serious complication post-transplantation. In an analysis of the US National Transplant Data, Sampaio *et al*[242] analyzed 200000 recipients of kidney, liver, heart and lung. The PTM incidence was 8.03, 11, 14.4 and 19.8 in KTx, LTx, HTx and LuTx respectively. The PTM recipients were older, mostly white and males in all SOTs.

A cohort study was conducted in Australia using population based, liver and cardiothoracic registries[243]. During a median 5-year follow-up, the risk of any cancer in the liver and cardiothoracic recipients, was significantly elevated compared to the general population [Standardized Incidence Ratio (SIR) = 2.62]. An excess risk was observed for 16 cancer types, predominantly cancers with a viral etiology. The adjusted HR for any cancer in all recipients was higher in heart compared to liver (HR = 1.29). Understanding the factors responsible for the higher cancer incidence in cardiothoracic compared to liver recipients has the potential to lead to targeted cancer prevention strategies in this high risk population.

Two interesting presentations at the ATC 2013 focused the association between the development of a skin cancer and the subsequent development of a solid organ tumor. Cho[244] analyzed data from OPTN/UNOS database and compared the incidence of solid tumors in organ recipients with and without melanoma skin cancer (NMSC). Developing a skin cancer was a risk factor for developing a solid tumor: 9.4% in those who developed a skin cancer *vs* 3.3% in those who did not.

A very similar study was conducted in Australia. McDonald[245] analyzed the data from Australia and New Zealand Dialysis and Transplantation (ANZDATA). They found that having a NMSC increased the risk of other cancers by 1.2%. These studies are interesting because skin cancers may be a useful tool to identify people at higher risk for developing other cancers.

The International Transplant Skin Cancer Collaborative (ITSCC) and its European counterpart: Skin Cancer in Organ Transplant Patients Europe (SCOPE) held by the end of 2012 a joint meeting that has been recently published[246].

The cutaneous squamous cell carcinoma (CSCC) incidence has been previously ascribed to immunosuppressive therapies. The decreased immunosurveillance by innate and adapted immune cells has been investigated and the specific role of macrophages. The direct effect of immune suppression on keratinocyte development has been postulated as well. Because of the need of CSCC epidemiology studies, was outlined an international collaboration between ITSCC and SCOPE to prospectively study CSCC in transplant patient.

**CONCLUSION**

In few fields of human medical knowledge, the science is so rapidly evolving as in organ transplantation. In this review the principal news that occurred by 2013 are described. By, because some news refers to meeting, consensus conference or guidelines held in the late 2012 but published in 2013; others on the contrary were held in 2013, but published in the first months of 2014.

In these conclusions we highlight several points, which in our opinion represent new frontiers in transplantation. While the donor pool is not as large as it would be necessary, the donor shift towards the so called ECD realize new problems in the organ allocations and in the organ preservation, Relevant news has been found in the field of antibody mediated rejection, both acute and chronic. This kind of rejection involves any solid organ, even if the majority of studies have been done in the kidneys. A new Banff conference has been held in 2013 and new classifications have been made whenever possible.

The ischemia reperfusion injury concerns also any organ. In this field the majority of researches have been made in liver transplantation. The innate immunity is involved and new drugs have been found or are on clinical trials. Pancreas transplantation is now a therapeutic option also for T2DM, even if a limiting factor is the shortage of pancreas available. Islet cell transplantation is improving with new techniques for implantation and for microencapsulation.

Heart transplantation has now optimal graft survival rate and also the MCS is evolving so to represent an alternative to transplantation in addition to bridge to transplantation. New strategies for primary graft dysfunction in lung transplantation have been found as well as a better understanding of the different types of chronic allograft dysfunction. New drugs appear at the horizon, principally for kidney transplantation. In particular, drugs targeting the B cells and the complement pathway are interesting, considering the relevance of ABMR. Other drugs for different organs such as liver, pancreatic islet and lung are being studied in clinical trials. Anti-inflammatory drugs enhance the effect of the immunosuppressant drugs.

The knowledge on tolerance is improving either applying bone marrow cells or mesenchimal stem cells. The infections and the cancers remain among the principal drawbacks in transplantation and several meetings and conferences have been held principally to elaborate guidelines to check and control HCV, HIV, CMV and others HHV.

The need to realize international registries for an improved knowledge of cancer epidemiology has been stressed by several authors. Finally a point of weakness in the field of transplantation is the differences that exist among the countries in the world. The different transplant rate depends also by the fact that in several countries peoples do not reach end stage disease. This probably represents the hardest frontier to be afforded.

**REFERENCES**

1 OPTN/SRTR 2012 Annual Data Report Introduction*. Am J Transplant* 2014; **14** Suppl 1: 8-10 [DOI: 10.1111/ajt.12578]

2 **Kasiske BL**, Skeans MA, Leighton TR, Ghimire V, Leppke SN, Israni AK. OPTN/SRTR 2011 Annual Data Report: international data. *Am J Transplant* 2013; **13** Suppl 1: 199-225 [PMID: 23237702 DOI: 10.1111/ajt.12026]

3 **Garcia GG**, Harden P, Chapman J. The global role of kidney transplantation. *Lancet* 2012; **379**: e36-e38 [PMID: 22405254 DOI: 10.1016/S0140-6736(12)60202-5]

4 **Israni AK**, Zaun D, Rosendale JD, Snyder JJ, Kasiske BL. OPTN/SRTR 2012 Annual Data Report: deceased organ donation. *Am J Transplant* 2014; **14** Suppl 1: 167-183 [PMID: 24373172 DOI: 10.1111/ajt.12585]

5 **Pondrom S**. Fewer living: a decline in living donors may be due to multiple factors. *Am J Transplant* 2014; **14**: 245-246 [PMID: 24472188 DOI: 10.1111/ajt.12657]

6 **Heaphy EL**, Goldfarb DA, Poggio ED, Buccini LD, Flechner SM, Schold JD. The impact of deceased donor kidney risk significantly varies by recipient characteristics. *Am J Transplant* 2013; **13**: 1001-1011 [PMID: 23406350 DOI: 10.1111/ajt.12154]

7 **Singh SK**, Kim SJ. Does expanded criteria donor status modify the outcomes of kidney transplantation from donors after cardiac death? *Am J Transplant* 2013; **13**: 329-336 [PMID: 23136921 DOI: 10.1111/j.1600-6143.2012.04311.x]

8 **Matsuno N**, Kobayashi E. Challenges in machine perfusion preservation for liver grafts from donation after circulatory death. *Transplant Res* 2013; **2**: 19 [PMID: 24283383 DOI: 10.1186/2047-1440-2-19]

9 **Bruns H**, Schemmer P. Machine perfusion in solid organ transplantation: where is the benefit? *Langenbecks Arch Surg* 2014; **399**: 421-427 [PMID: 24429900 DOI: 10.1007/s00423-014-1161-2]

10 **Rodrigue JR**, Schold JD, Mandelbrot DA. The decline in living kidney donation in the United States: random variation or cause for concern? *Transplantation* 2013; **96**: 767-773 [PMID: 23759882 DOI: 10.1097/TP.0b013e318298fa61]

11 **Tong A**, Chapman JR, Wong G, Josephson MA, Craig JC. Public awareness and attitudes to living organ donation: systematic review and integrative synthesis. *Transplantation* 2013; **96**: 429-437 [PMID: 23677051 DOI: 10.1097/TP.0b013e31829282ac]

12 **Campbell P**. Clinical relevance of human leukocyte antigen antibodies in liver, heart, lung and intestine transplantation. *Curr Opin Organ Transplant* 2013; **18**: 463-469 [PMID: 23838652 DOI: 10.1097/MOT.0b013e3283636c71]

13 **Süsal C**, Roelen DL, Fischer G, Campos EF, Gerbase-DeLima M, Hönger G, Schaub S, Lachmann N, Martorell J, Claas F. Algorithms for the determination of unacceptable HLA antigen mismatches in kidney transplant recipients. *Tissue Antigens* 2013; **82**: 83-92 [PMID: 23718733 DOI: 10.1111/tan.12137]

14 **Böhmig GA**, Fidler S, Christiansen FT, Fischer G, Ferrari P. Transnational validation of the Australian algorithm for virtual crossmatch allocation in kidney paired donation. *Hum Immunol* 2013; **74**: 500-505 [PMID: 23380140 DOI: 10.1016/j.humimm.2013.01.029]

15 **Blumberg JM**, Gritsch HA, Reed EF, Cecka JM, Lipshutz GS, Danovitch GM, McGuire S, Gjertson DW, Veale JL. Kidney paired donation in the presence of donor-specific antibodies. *Kidney Int* 2013; **84**: 1009-1016 [PMID: 23715120 DOI: 10.1038/ki.2013.206]

16 **Garonzik-Wang JM**, Sullivan B, Hiller JM, Cass V, Tchervenkow J, Feldman L, Baran D, Chaudhury P, Cantarovich M, Segev DL, Montgomery RA. International kidney paired donation. *Transplantation* 2013; **96**: e55-e56 [PMID: 24100847 DOI: 10.1097/TP.0b013e3182a68879]

17 **Sharif A**. Unspecified kidney donation--a review of principles, practice and potential. *Transplantation* 2013; **95**: 1425-1430 [PMID: 23778567 DOI: 10.1097/TP.0b013e31829282eb]

18 **Matas AJ**, Smith JM, Skeans MA, Thompson B, Gustafson SK, Schnitzler MA, Stewart DE, Cherikh WS, Wainright JL, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2012 Annual Data Report: kidney. *Am J Transplant* 2014; **14 Suppl 1**: 11-44 [PMID: 24373166 DOI: 10.1111/ajt.12579]

19 **Gondos A**, Döhler B, Brenner H, Opelz G. Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. *Transplantation* 2013; **95**: 267-274 [PMID: 23060279 DOI: 10.1097/TP.0b013e3182708ea8]

20 **Willoughby LM**, Fukami S, Bunnapradist S, Gavard JA, Lentine KL, Hardinger KL, Burroughs TE, Takemoto SK, Schnitzler MA. Health insurance considerations for adolescent transplant recipients as they transition to adulthood. *Pediatr Transplant* 2007; **11**: 127-131 [PMID: 17300489 DOI: 10.1111/j.1399-3046.2006.00639.x]

21 **Kennedy J**, Erb C. Prescription noncompliance due to cost among adults with disabilities in the United States. *Am J Public Health* 2002; **92**: 1120-1124 [PMID: 12084695]

22 **Butler JA**, Roderick P, Mullee M, Mason JC, Peveler RC. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. *Transplantation* 2004; **77**: 769-776 [PMID: 15021846]

23 **Woodward RS**, Page TF, Soares R, Schnitzler MA, Lentine KL, Brennan DC. Income-related disparities in kidney transplant graft failures are eliminated by Medicare's immunosuppression coverage. *Am J Transplant* 2008; **8**: 2636-2646 [PMID: 19032227 DOI: 10.1111/j.1600-6143.2008.02422.x]

24 **Schold JD**, Heaphy EL, Buccini LD, Poggio ED, Srinivas TR, Goldfarb DA, Flechner SM, Rodrigue JR, Thornton JD, Sehgal AR. Prominent impact of community risk factors on kidney transplant candidate processes and outcomes. *Am J Transplant* 2013; **13**: 2374-2383 [PMID: 24034708 DOI: 10.1111/ajt.12349]

25 **Cavaillé-Coll M**, Bala S, Velidedeoglu E, Hernandez A, Archdeacon P, Gonzalez G, Neuland C, Meyer J, Albrecht R. Summary of FDA workshop on ischemia reperfusion injury in kidney transplantation. *Am J Transplant* 2013; **13**: 1134-1148 [PMID: 23566221 DOI: 10.1111/ajt.12210]

26 **Pepe MS**, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y. Phases of biomarker development for early detection of cancer. *J Natl Cancer Inst* 2001; **93**: 1054-1061 [PMID: 11459866]

27 **Linkermann A**, Hackl MJ, Kunzendorf U, Walczak H, Krautwald S, Jevnikar AM. Necroptosis in immunity and ischemia-reperfusion injury. *Am J Transplant* 2013; **13**: 2797-2804 [PMID: 24103029 DOI: 10.1111/ajt.12448]

28 **Lau A**, Wang S, Jiang J, Haig A, Pavlosky A, Linkermann A, Zhang ZX, Jevnikar AM. RIPK3-mediated necroptosis promotes donor kidney inflammatory injury and reduces allograft survival. *Am J Transplant* 2013; **13**: 2805-2818 [PMID: 24103001 DOI: 10.1111/ajt.12447]

29 **Mannon RB**. Necroptosis in solid organ transplantation: a missing link to immune activation? *Am J Transplant* 2013; **13**: 2785-2786 [PMID: 24103049 DOI: 10.1111/ajt.12450]

30 **Shuh M**, Bohorquez H, Loss GE, Cohen AJ. Tumor Necrosis Factor-α: Life and Death of Hepatocytes During Liver Ischemia/Reperfusion Injury. *Ochsner J* 2013; **13**: 119-130 [PMID: 23531747]

31 **Djamali A**, Kaufman DB, Ellis TM, Zhong W, Matas A, Samaniego M. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. *Am J Transplant* 2014; **14**: 255-271 [PMID: 24401076 DOI: 10.1111/ajt.12589]

32 **Taniguchi M**, Rebellato LM, Cai J, Hopfield J, Briley KP, Haisch CE, Catrou PG, Bolin P, Parker K, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI. Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. *Am J Transplant* 2013; **13**: 2577-2589 [PMID: 23941128 DOI: 10.1111/ajt.12395]

33 **Giral M**, Foucher Y, Dufay A, Van Huyen JP, Renaudin K, Moreau A, Philippe A, Hegner B, Dechend R, Heidecke H, Brouard S, Cesbron A, Castagnet S, Devys A, Soulillou JP, Dragun D. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. *Am J Transplant* 2013; **13**: 2567-2576 [PMID: 23919486 DOI: 10.1111/ajt.12397]

34 **Porcheray F**, Fraser JW, Gao B, McColl A, DeVito J, Dargon I, Helou Y, Wong W, Girouard TC, Saidman SL, Colvin RB, Palmisano A, Maggiore U, Vaglio A, Smith RN, Zorn E. Polyreactive antibodies developing amidst humoral rejection of human kidney grafts bind apoptotic cells and activate complement. *Am J Transplant* 2013; **13**: 2590-2600 [PMID: 23919437 DOI: 10.1111/ajt.12394]

35 **Sis B**, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. *Am J Transplant* 2009; **9**: 2312-2323 [PMID: 19681822 DOI: 10.1111/j.1600-6143.2009.02761.x]

36 **Sellarés J**, Reeve J, Loupy A, Mengel M, Sis B, Skene A, de Freitas DG, Kreepala C, Hidalgo LG, Famulski KS, Halloran PF. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. *Am J Transplant* 2013; **13**: 971-983 [PMID: 23414212 DOI: 10.1111/ajt.12150]

37 **Moreau A**, Varey E, Anegon I, Cuturi MC. Effector mechanisms of rejection. *Cold Spring Harb Perspect Med* 2013; **3**: [PMID: 24186491 DOI: 10.1101/cshperspect.a015461]

38 **Krneta T**, Gillgrass A, Ashkar AA. The influence of macrophages and the tumor microenvironment on natural killer cells. *Curr Mol Med* 2013; **13**: 68-79 [PMID: 22834841 DOI: 10.2174/1566524011307010068]

39 **Haas M**, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, Castro MC, David DS, David-Neto E, Bagnasco SM, Cendales LC, Cornell LD, Demetris AJ, Drachenberg CB, Farver CF, Farris AB, Gibson IW, Kraus E, Liapis H, Loupy A, Nickeleit V, Randhawa P, Rodriguez ER, Rush D, Smith RN, Tan CD, Wallace WD, Mengel M. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. *Am J Transplant* 2014; **14**: 272-283 [PMID: 24472190 DOI: 10.1111/ajt.12590]

40 **Bachelet T**, Couzi L, Lepreux S, Legeret M, Pariscoat G, Guidicelli G, Merville P, Taupin JL. Kidney intragraft donor-specific antibodies as determinant of antibody-mediated lesions and poor graft outcome. *Am J Transplant* 2013; **13**: 2855-2864 [PMID: 24102857 DOI: 10.1111/ajt.12438]

41 **Sis B**. Intragraft donor-specific antibody detection: a new test to dichotomize HLA alloantibodies into high and low injurious activity. *Am J Transplant* 2013; **13**: 2787-2789 [PMID: 24102879 DOI: 10.1111/ajt.12440]

42 **Volk HD**, Sawitzki B, Reinke P. Molecular analysis of renal allograft biopsies--more than a nice toy for researchers? *Am J Transplant* 2013; **13**: 539-540 [PMID: 23437880 DOI: 10.1111/ajt.12081]

43 **Reeve J**, Sellarés J, Mengel M, Sis B, Skene A, Hidalgo L, de Freitas DG, Famulski KS, Halloran PF. Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. *Am J Transplant* 2013; **13**: 645-655 [PMID: 23356949 DOI: 10.1111/ajt.12079]

44 **Famulski KS**, Reeve J, de Freitas DG, Kreepala C, Chang J, Halloran PF. Kidney transplants with progressing chronic diseases express high levels of acute kidney injury transcripts. *Am J Transplant* 2013; **13**: 634-644 [PMID: 23356967 DOI: 10.1111/ajt.12080]

45 **Halloran PF**, Pereira AB, Chang J, Matas A, Picton M, De Freitas D, Bromberg J, Serón D, Sellarés J, Einecke G, Reeve J. Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: an international prospective study (INTERCOM). *Am J Transplant* 2013; **13**: 2865-2874 [PMID: 24119109 DOI: 10.1111/ajt.12465]

46 **Halloran PF**, Pereira AB, Chang J, Matas A, Picton M, De Freitas D, Bromberg J, Serón D, Sellarés J, Einecke G, Reeve J. Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: The INTERCOM study. *Am J Transplant* 2013; **13**: 2352-2363 [PMID: 23915426 DOI: 10.1111/ajt.12387]

47 **Suthanthiran M**, Schwartz JE, Ding R, Abecassis M, Dadhania D, Samstein B, Knechtle SJ, Friedewald J, Becker YT, Sharma VK, Williams NM, Chang CS, Hoang C, Muthukumar T, August P, Keslar KS, Fairchild RL, Hricik DE, Heeger PS, Han L, Liu J, Riggs M, Ikle DN, Bridges ND, Shaked A. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. *N Engl J Med* 2013; **369**: 20-31 [PMID: 23822777 DOI: 10.1056/NEJMoa1215555]

48 **Israni AK**, Skeans MA, Gustafson SK, Schnitzler MA, Wainright JL, Carrico RJ, Tyler KH, Kades LA, Kandaswamy R, Snyder JJ, Kasiske BL. OPTN/SRTR 2012 Annual Data Report: pancreas. *Am J Transplant* 2014; **14** Suppl 1: 45-68 [PMID: 24373167 DOI: 10.1111/ajt.12580]

49 **Schulz T**, Pries A, Caliebe A, Kapischke M. Long-term survival after simultaneous pancreas-kidney transplantation with primary function of at least one year--a single-center experience. *Ann Transplant* 2014; **19**: 106-111 [PMID: 24576894 DOI: 10.12659/AOT.889715]

50 **Montiel-Casado MC**, Pérez-Daga JA, Aranda-Narváez JM, Fernández-Burgos I, Sánchez-Pérez B, León-Díaz FJ, Cabello-Díaz M, Rodríguez-Burgos D, Hernández-Marrero D, Santoyo-Santoyo J. Pancreas graft survival in simultaneous pancreas-kidney versus pancreas-after-kidney and pancreas alone transplantations: a single institution experience. *Transplant Proc* 2013; **45**: 3609-3611 [PMID: 24314973 DOI: 10.1016/j.transproceed.2013.10.019]

51 **Lindahl JP**, Hartmann A, Horneland R, Holdaas H, Reisæter AV, Midtvedt K, Leivestad T, Oyen O, Jenssen T. Improved patient survival with simultaneous pancreas and kidney transplantation in recipients with diabetic end-stage renal disease. *Diabetologia* 2013; **56**: 1364-1371 [PMID: 23549518 DOI: 10.1007/s00125-013-2888-y]

52 CITR Investigators 2011 Update from the Collaborative Islet Transplant Registry. *Am J Transplant* 2012; **12** (Suppl 3): S161. [DOI: 10.1111/j. 1600-6143.2012.04112.x]

53 **Cohen DJ**, Ratner LE. Type 2 diabetes: the best transplant option is still uncertain. *Clin J Am Soc Nephrol* 2012; **7**: 530-532 [PMID: 22442186 DOI: 10.2215/CJN.02120212]

54 **Gruessner AC**, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. *Clin Transplant* 2005; **19**: 433-455 [PMID: 16008587 DOI: 10.1111/j.1399-0012.2005.00378.x]

55 **Orlando G**, Stratta RJ, Light J. Pancreas transplantation for type 2 diabetes mellitus. *Curr Opin Organ Transplant* 2011; **16**: 110-115 [PMID: 21150617 DOI: 10.1097/MOT.0b013e3283424d1f]

56 **Sampaio MS**, Kuo HT, Bunnapradist S. Outcomes of simultaneous pancreas-kidney transplantation in type 2 diabetic recipients. *Clin J Am Soc Nephrol* 2011; **6**: 1198-1206 [PMID: 21441123 DOI: 10.2215/CJN.06860810]

57 **Margreiter C**, Resch T, Oberhuber R, Aigner F, Maier H, Sucher R, Schneeberger S, Ulmer H, Bösmüller C, Margreiter R, Pratschke J, Öllinger R. Combined pancreas-kidney transplantation for patients with end-stage nephropathy caused by type-2 diabetes mellitus. *Transplantation* 2013; **95**: 1030-1036 [PMID: 23407544 DOI: 10.1097/TP.0b013e3182861945]

58 **Sener A**, Cooper M, Bartlett ST. Is there a role for pancreas transplantation in type 2 diabetes mellitus? *Transplantation* 2010; **90**: 121-123 [PMID: 20562677 DOI: 10.1097/TP.0b013e3181e5b7e6]

59 **Niederhaus SV**, Leverson GE, Lorentzen DF, Robillard DJ, Sollinger HW, Pirsch JD, Torrealba JR, Odorico JS. Acute cellular and antibody-mediated rejection of the pancreas allograft: incidence, risk factors and outcomes. *Am J Transplant* 2013; **13**: 2945-2955 [PMID: 24102905 DOI: 10.1111/ajt.12443]

60 **Drachenberg CB**, Torrealba JR, Nankivell BJ, Rangel EB, Bajema IM, Kim DU, Arend L, Bracamonte ER, Bromberg JS, Bruijn JA, Cantarovich D, Chapman JR, Farris AB, Gaber L, Goldberg JC, Haririan A, Honsová E, Iskandar SS, Klassen DK, Kraus E, Lower F, Odorico J, Olson JL, Mittalhenkle A, Munivenkatappa R, Paraskevas S, Papadimitriou JC, Randhawa P, Reinholt FP, Renaudin K, Revelo P, Ruiz P, Samaniego MD, Shapiro R, Stratta RJ, Sutherland DE, Troxell ML, Voska L, Seshan SV, Racusen LC, Bartlett ST. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema. *Am J Transplant* 2011; **11**: 1792-1802 [PMID: 21812920 DOI: 10.1111/j.1600-6143.2011.03670.x]

61 **Shapiro AM**, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. *N Engl J Med* 2000; **343**: 230-238 [PMID: 10911004 DOI: 10.1056/NEJM200007273430401]

62 **Jahansouz C**, Jahansouz C, Kumer SC, Brayman KL. Evolution of β-Cell Replacement Therapy in Diabetes Mellitus: Islet Cell Transplantation. *J Transplant* 2011; DOI: 10.1155/2011/247959

63 **Pepper AR**, Gala-Lopez B, Ziff O, Shapiro AJ. Current status of clinical islet transplantation. *World J Transplant* 2013; **3**: 48-53 [PMID: 24392308 DOI: 10.5500/wjt.v3.i4.48]

64 **Masharani U**, Moassesfar S, Frassetto L, Szot G, Tavakol M, McElroy J, Ramos M, Johnson K, Stock PG, Posselt A. Long Term Insulin Independence After Islet Transplant Alone (ITA) and Pancreas Transplant Alone (PTA) in Patients with Type 1 Diabetes (T1D) – A Single Institution Experience. *Transplantation* 2013; **96**: 6S, S44

65 **Tang Q**, Posselt A, Szot GL, Melli K, Pauli M, Frasetto L , Masharani U ,Fong L, Stock PG. Immunological Impact of Efalizumab Versus Belatacept in Islet Transplantation. *Transplantation* 2013; **96**: 6S, 115

66 **Naziruddin B,** Takita M, Kunnathodi F, Shahbazov R, Kanak M, Lawrence M, Onaca N, Levy M. Early Treatment with Etanercept and Anakinra Prevents Islet Graft Damage in Clinical Islet Auto-transplantation. *Transplantation* 2013; **96**: 6S, 5

67 **Maffi P**, Daffonchio L, Ruffini PA, Allegretti M, Citro A, Magistretti P, Melzi R, Mercalli A, Nano R, Sordi V, Secchi A, Piemonti L. Islet Allotransplantation in Type 1 Diabetes: Phase 2 Pilot Study with CXCL8 Inhibitor (reparixin). *Transplantation* 2013; **96:** 6S, 4

68 **Citro A**, Cantarelli E, Maffi P, Nano R, Melzi R, Mercalli A, Dugnani E, Sordi V, Magistretti P, Daffonchio L, Ruffini PA, Allegretti M, Secchi A, Bonifacio E, Piemonti L. CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. *J Clin Invest* 2012; **122**: 3647-3651 [PMID: 22996693 DOI: 10.1172/JCI63089]

69 **Takita M**, Shahabazov R, Kunnathodi F, Mueller C, Kurup P, Kanak M, Lawrence M, Onaca N, Ueno H, Naziruddin B, Levy M. Early Loss of Transplanted Allogeneic Islets Despite T-Cell Depleting Induction: The Role of Autoimmunity in Clinical Islet Transplantation. *Transplantation* 2013; **96**: 6S, 121

70 **Pepper AR**, Gala-Lopez B, Ziff O, Shapiro AM. Revascularization of transplanted pancreatic islets and role of the transplantation site. *Clin Dev Immunol* 2013 DOI: 10.1155/2013/352315

71 **Henriksnäs J**, Lau J, Zang G, Berggren PO, Köhler M, Carlsson PO. Markedly decreased blood perfusion of pancreatic islets transplanted intraportally into the liver: disruption of islet integrity necessary for islet revascularization. *Diabetes* 2012; **61**: 665-673 [PMID: 22315321 DOI: 10.2337/db10-0895]

72 **Bellin M**, Hering B, Balamurugan AN, Parazzoli S, Oseid E, Dunn T, Beilman G, Sutherland D, Robertson RP. Alpha Cells in Intraperitoneal, but not Intra-hepatic, Auto-islet Transplants Function Normally During Hypoglycemia in Humans After Total Pancreatectomy and Islet Auto-transplantation. *Transplantation* 2013; **96**: 6S, 7

73 **Espes D,** Lau J, Quach M, Palmer AF, Carisson PO. Hypoxia in Islets After Intramuscular Transplantation can be Overcome by Co-Implantation of Polymerized Hemoglobin. *Transplantation* 2013; **96**: 6S, 44

74 **Buder B**, Alexander M, Krishnan R, Chapman DW, Lakey JR. Encapsulated islet transplantation: strategies and clinical trials. *Immune Netw* 2013; **13**: 235-239 [PMID: 24385941 DOI: 10.4110/in.2013.13.6.235]

75 **Kim WR**, Smith JM, Skeans MA, Schladt DP, Schnitzler MA, Edwards EB, Harper AM, Wainright JL, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2012 Annual Data Report: liver. *Am J Transplant* 2014; **14 Suppl 1**: 69-96 [PMID: 24373168 DOI: 10.1111/ajt.12581]

76 **Lodhi SA**, Lamb KE, Meier-Kriesche HU. Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. *Am J Transplant* 2011; **11**: 1226-1235 [PMID: 21564524 DOI: 10.1111/j.1600-6143.2011.03539.x]

77 **Schoening WN**, Buescher N, Rademacher S, Andreou A, Kuehn S, Neuhaus R, Guckelberger O, Puhl G, Seehofer D, Neuhaus P. Twenty-year longitudinal follow-up after orthotopic liver transplantation: a single-center experience of 313 consecutive cases. *Am J Transplant* 2013; **13**: 2384-2394 [PMID: 23915357 DOI: 10.1111/ajt.12384]

78 **Jain A**, Singhal A, Fontes P, Mazariegos G, DeVera ME, Cacciarelli T, Lopez RC, Sindhi R, Humar A, Marsh JW. One thousand consecutive primary liver transplants under tacrolimus immunosuppression: a 17- to 20-year longitudinal follow-up. *Transplantation* 2011; **91**: 1025-1030 [PMID: 21378604 DOI: 10.1097/TP.0b013e3182129215]

79 **Duffy JP**, Kao K, Ko CY, Farmer DG, McDiarmid SV, Hong JC, Venick RS, Feist S, Goldstein L, Saab S, Hiatt JR, Busuttil RW. Long-term patient outcome and quality of life after liver transplantation: analysis of 20-year survivors. *Ann Surg* 2010; **252**: 652-661 [PMID: 20881772 DOI: 10.1097/SLA.0b013e3181f5f23a]

80 **Adam R**, Karam V, Delvart V, O'Grady J, Mirza D, Klempnauer J, Castaing D, Neuhaus P, Jamieson N, Salizzoni M, Pollard S, Lerut J, Paul A, Garcia-Valdecasas JC, Rodríguez FS, Burroughs A. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). *J Hepatol* 2012; **57**: 675-688 [PMID: 22609307 DOI: 10.1016/j.jhep.2012.04.015]

81 **Kasahara M**, Umeshita K, Inomata Y, Uemoto S. Long-term outcomes of pediatric living donor liver transplantation in Japan: an analysis of more than 2200 cases listed in the registry of the Japanese Liver Transplantation Society. *Am J Transplant* 2013; **13**: 1830-1839 [PMID: 23711238 DOI: 10.1111/ajt.12276]

82 **Singal AK**, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. *Transplantation* 2013; **95**: 755-760 [PMID: 23370710 DOI: 10.1097/TP.0b013e31827afb3a]

83 **Burton JR**, Everson GT. Management of the transplant recipient with chronic hepatitis C. *Clin Liver Dis* 2013; **17**: 73-91 [PMID: 23177284 DOI: 10.1016/j.cld.2012.09.013]

84 **Jacobson IM**, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med* 2011; **364**: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912]

85 **Poordad F**, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med* 2011; **364**: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]

86 **Garg V**, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. *Hepatology* 2011; **54**: 20-27 [PMID: 21618566 DOI: 10.1002/hep.24443]

87 **Croagh CM**, Lubel J. Advances in the management of hepatitis C. *Intern Med J* 2013; **43**: 1265-1271 [PMID: 24330361 DOI: 10.1111/imj.12304]

88 **Sautto GA**, Diotti RA, Clementi M. New therapeutic options for HCV infection in the monoclonal antibody era. *New Microbiol* 2012; **35**: 387-397 [PMID: 23109006]

89 **Datta G**, Fuller BJ, Davidson BR. Molecular mechanisms of liver ischemia reperfusion injury: insights from transgenic knockout models. *World J Gastroenterol* 2013; **19**: 1683-1698 [PMID: 23555157 DOI: 10.3748/wjg.v19.i11.1683]

90 **Mendes-Braz M**, Elias-Miró M, Jiménez-Castro MB, Casillas-Ramírez A, Ramalho FS, Peralta C. The current state of knowledge of hepatic ischemia-reperfusion injury based on its study in experimental models. *J Biomed Biotechnol* 2012; DOI: 10.1155/2012/298657

91 **Akhtar MZ**, Henderson T, Sutherland A, Vogel T, Friend PJ. Novel approaches to preventing ischemia-reperfusion injury during liver transplantation. *Transplant Proc* 2013; **45**: 2083-2092 [PMID: 23953517 DOI: 10.1016/j.transproceed.2013.04.004]

92 **Elias-Miró M**, Jiménez-Castro MB, Rodés J, Peralta C. Current knowledge on oxidative stress in hepatic ischemia/reperfusion. *Free Radic Res* 2013; **47**: 555-568 [PMID: 23738581 DOI: 10.3109/10715762.2013.811721]

93 **Genovés P**, García D, Cejalvo D, Martin A, Zaragoza C, Toledo AH, Toledo-Pereyra LH, Lloris-Carsi JM. Pentoxifylline in liver ischemia and reperfusion. *J Invest Surg* 2014; **27**: 114-124 [PMID: 24143911 DOI: 10.3109/08941939.2013.835454]

94 **Tiriveedhi V**, Upadhya GA, Busch RA, Gunter KL, Dines JN, Knolhoff BL, Jia J, Sarma NJ, Ramachandran S, Anderson CD, Mohanakumar T, Chapman WC. Protective role of bortezomib in steatotic liver ischemia/reperfusion injury through abrogation of MMP activation and YKL-40 expression. *Transpl Immunol* 2014; **30**: 93-98 [PMID: 24380732 DOI: 10.1016/j.trim.2013.12.003]

95 **Saidi RF**, Rajeshkumar B, Shariftabrizi A, Dresser K, Walter O. Human C1 inhibitor attenuates liver ischemia-reperfusion injury and promotes liver regeneration. *J Surg Res* 2014; **187**: 660-666 [PMID: 24433870 DOI: 10.1016/j.jss.2013.09.009]

96 **Iwatsuki S**, Rabin BS, Shaw BW, Starzl TE. Liver transplantation against T cell-positive warm crossmatches. *Transplant Proc* 1984; **16**: 1427-1429 [PMID: 6390842]

97 **Gordon RD**, Fung JJ, Markus B, Fox I, Iwatsuki S, Esquivel CO, Tzakis A, Todo S, Starzl TE. The antibody crossmatch in liver transplantation. *Surgery* 1986; **100**: 705-715 [PMID: 3532391]

98 **Ruiz R**, Tomiyama K, Campsen J, Goldstein RM, Levy MF, McKenna GJ, Onaca N, Susskind B, Tillery GW, Klintmalm GB. Implications of a positive crossmatch in liver transplantation: a 20-year review. *Liver Transpl* 2012; **18**: 455-460 [PMID: 22139972 DOI: 10.1002/lt.22474]

99 **Takaya S**, Bronsther O, Iwaki Y, Nakamura K, Abu-Elmagd K, Yagihashi A, Demetris AJ, Kobayashi M, Todo S, Tzakis AG. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. *Transplantation* 1992; **53**: 400-406 [PMID: 1371195]

100 **Ogura K**, Koyama H, Takemoto S, Terasaki PI, Busuttil RW. Significance of a positive crossmatch on outcome in human liver transplantation. *Transplant Proc* 1992; **24**: 1465 [PMID: 1496620]

101 **O'Leary JG**, Kaneku H, Demetris AJ, Marr JD, Shiller SM, Susskind BM, Tillery GW, Terasaki PI, Klintmalm GB. Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. *Liver Transpl* 2014; **20**: 218-227 [PMID: 24382837 DOI: 10.1002/lt.23788]

102 **Kaneku H**, O'Leary JG, Banuelos N, Jennings LW, Susskind BM, Klintmalm GB, Terasaki PI. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. *Am J Transplant* 2013; **13**: 1541-1548 [PMID: 23721554 DOI: 10.1111/ajt.12212]

103 **Hu J**, Wang Z, Tan CJ, Liao BY, Zhang X, Xu M, Dai Z, Qiu SJ, Huang XW, Sun J, Sun QM, He YF, Song K, Pan Q, Wu Y, Fan J, Zhou J. Plasma microRNA, a potential biomarker for acute rejection after liver transplantation. *Transplantation* 2013; **95**: 991-999 [PMID: 23466638 DOI: 10.1097/TP.0b013e31828618d8]

104 **Wei L**, Gong X, Martinez OM, Krams SM. Differential expression and functions of microRNAs in liver transplantation and potential use as non-invasive biomarkers. *Transpl Immunol* 2013; **29**: 123-129 [PMID: 24001411 DOI: 10.1016/j.trim.2013.08.005]

105 **Colvin-Adams M**, Smith JM, Heubner BM, Skeans MA, Edwards LB, Waller C, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2011 Annual Data Report: heart. *Am J Transplant* 2013; **13 Suppl 1**: 119-148 [PMID: 23237699 DOI: 10.1111/ajt.12023]

106 **Lund LH**, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD, Dobbels F, Kirk R, Rahmel AO, Yusen RD, Stehlik J. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report--2013; focus theme: age. *J Heart Lung Transplant* 2013; **32**: 951-964 [PMID: 24054804 DOI: 10.1016/j.healun.2013.08.006]

107 **Pondrom S**. Heart failure options broaden. *Am J Transplant* 2013; **13**: 827-828 [PMID: 23551626 DOI: 10.1111/ajt.12231]

108 **Slaughter MS**, Pagani FD, McGee EC, Birks EJ, Cotts WG, Gregoric I, Howard Frazier O, Icenogle T, Najjar SS, Boyce SW, Acker MA, John R, Hathaway DR, Najarian KB, Aaronson KD. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. *J Heart Lung Transplant* 2013; **32**: 675-683 [PMID: 23796152 DOI: 10.1016/j.healun.2013.04.004]

109 **Taghavi S**, Jayarajan SN, Komaroff E, Mangi AA. Continuous flow left ventricular assist device technology has influenced wait times and affected donor allocation in cardiac transplantation. *J Thorac Cardiovasc Surg* 2014; **147**: 1966-171, 1971.e1 [PMID: 24613158 DOI: 10.1016/j.jtcvs.2014.02.001]

110 **Sutcliffe P**, Connock M, Pulikottil-Jacob R, Kandala NB, Suri G, Gurung T, Grove A, Shyangdan D, Briscoe S, Maheswaran H, Clarke A. Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model. *Health Technol Assess* 2013; **17**: 1-499, v-vi [PMID: 24280231 DOI: 10.3310/hta17530]

111 **Feldman D**, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, Morgan JA, Arabia F, Bauman ME, Buchholz HW, Deng M, Dickstein ML, El-Banayosy A, Elliot T, Goldstein DJ, Grady KL, Jones K, Hryniewicz K, John R, Kaan A, Kusne S, Loebe M, Massicotte MP, Moazami N, Mohacsi P, Mooney M, Nelson T, Pagani F, Perry W, Potapov EV, Eduardo Rame J, Russell SD, Sorensen EN, Sun B, Strueber M, Mangi AA, Petty MG, Rogers J. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. *J Heart Lung Transplant* 2013; **32**: 157-187 [PMID: 23352391 DOI: 10.1016/j.healun.2012.09.013]

112 **Kilic A**, Allen JG, Weiss ES. Validation of the United States-derived Index for Mortality Prediction After Cardiac Transplantation (IMPACT) using international registry data. *J Heart Lung Transplant* 2013; **32**: 492-498 [PMID: 23474362 DOI: 10.1016/j.healun.2013.02.001]

113 **Smits JM**, de Vries E, De Pauw M, Zuckermann A, Rahmel A, Meiser B, Laufer G, Reichenspurner H, Strueber M. Is it time for a cardiac allocation score? First results from the Eurotransplant pilot study on a survival benefit-based heart allocation. *J Heart Lung Transplant* 2013; **32**: 873-880 [PMID: 23628111 DOI: 10.1016/j.healun.2013.03.015]

114 **Smith JD**, Banner NR, Hamour IM, Ozawa M, Goh A, Robinson D, Terasaki PI, Rose ML. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. *Am J Transplant* 2011; **11**: 312-319 [PMID: 21219570 DOI: 10.1111/j.1600-6143.2010.03383.x]

115 **Smith JD**, Hamour IM, Banner NR, Rose ML. C4d fixing, luminex binding antibodies - a new tool for prediction of graft failure after heart transplantation. *Am J Transplant* 2007; **7**: 2809-2815 [PMID: 17908268 DOI: 10.1111/j.1600-6143.2007.01991.x]

116 **Smith JD**, Hamour IM, Burke MM, Mahesh B, Stanford RE, Haj-Yahia S, Robinson DR, Kaul P, Yacoub MH, Banner NR, Rose ML. A reevaluation of the role of IgM Non-HLA antibodies in cardiac transplantation. *Transplantation* 2009; **87**: 864-871 [PMID: 19300190 DOI: 10.1097/TP.0b013e31819a65fa]

117 **Berry GJ**, Burke MM, Andersen C, Bruneval P, Fedrigo M, Fishbein MC, Goddard M, Hammond EH, Leone O, Marboe C, Miller D, Neil D, Rassl D, Revelo MP, Rice A, Rene Rodriguez E, Stewart S, Tan CD, Winters GL, West L, Mehra MR, Angelini A. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. *J Heart Lung Transplant* 2013; **32**: 1147-1162 [PMID: 24263017 DOI: 10.1016/j.healun.2013.08.011]

118 **Costello JP**, Mohanakumar T, Nath DS. Mechanisms of chronic cardiac allograft rejection. *Tex Heart Inst J* 2013; **40**: 395-399 [PMID: 24082367]

119 **Eisen HJ**, Kobashigawa J, Starling RC, Pauly DF, Kfoury A, Ross H, Wang SS, Cantin B, Van Bakel A, Ewald G, Hirt S, Lehmkuhl H, Keogh A, Rinaldi M, Potena L, Zuckermann A, Dong G, Cornu-Artis C, Lopez P. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. *Am J Transplant* 2013; **13**: 1203-1216 [PMID: 23433101 DOI: 10.1111/ajt.12181]

120 **Kobashigawa JA**, Pauly DF, Starling RC, Eisen H, Ross H, Wang SS, Cantin B, Hill JA, Lopez P, Dong G, Nicholls SJ. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial. *JACC Heart Fail* 2013; **1**: 389-399 [PMID: 24621971 DOI: 10.1016/j.jchf.2013.07.002]

121 **Mehra MR**. Advancing immunosuppression in heart transplantation: "one step forward, two steps back. *Am J Transplant* 2013; **13**: 1119-1120 [PMID: 23621159 DOI: 10.1111/ajt.12177]

122 **Khandhar SJ**, Yamamoto H, Teuteberg JJ, Shullo MA, Bezerra HG, Costa MA, Selzer F, Lee JS, Marroquin OC, McNamara DM, Mulukutla SR, Toma C. Optical coherence tomography for characterization of cardiac allograft vasculopathy after heart transplantation (OCTCAV study). *J Heart Lung Transplant* 2013; **32**: 596-602 [PMID: 23499356 DOI: 10.1016/j.healun.2013.02.005]

123 **Valapour M**, Skeans MA, Heubner BM, Smith JM, Schnitzler MA, Hertz MI, Edwards LB, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2012 Annual Data Report: lung. *Am J Transplant* 2014; **14 Suppl 1**: 139-165 [PMID: 24373171 DOI: 10.1111/ajt.12584]

124 **Yusen RD**, Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, Kirk R, Lund LH, Rahmel AO, Stehlik J. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Adult Lung and Heart-Lung Transplant Report--2013; focus theme: age. *J Heart Lung Transplant* 2013; **32**: 965-978 [PMID: 24054805 DOI: 10.1016/j.healun.2013.08.007]

125 **Shah RJ**, Kotloff RM. Lung transplantation for obstructive lung diseases. *Semin Respir Crit Care Med* 2013; **34**: 288-296 [PMID: 23821504 DOI: 10.1055/s-0033-1348468]

126 **Gottlieb J**. Lung transplantation for interstitial lung diseases and pulmonary hypertension. *Semin Respir Crit Care Med* 2013; **34**: 281-287 [PMID: 23821503 DOI: 10.1055/s-0033-1348462]

127 **Corris PA**. Lung transplantation for cystic fibrosis and bronchiectasis. *Semin Respir Crit Care Med* 2013; **34**: 297-304 [PMID: 23821505 DOI: 10.1055/s-0033-1348469]

128 **Snell GI**, Paraskeva M, Westall GP. Donor selection and management. *Semin Respir Crit Care Med* 2013; **34**: 361-370 [PMID: 23821510 DOI: 10.1055/s-0033-1348464]

129 **Bittle GJ**, Sanchez PG, Kon ZN, Claire Watkins A, Rajagopal K, Pierson RN, Gammie JS, Griffith BP. The use of lung donors older than 55 years: a review of the United Network of Organ Sharing database. *J Heart Lung Transplant* 2013; **32**: 760-768 [PMID: 23664760 DOI: 10.1016/j.healun.2013.04.012]

130 **Sommer W**, Kühn C, Tudorache I, Avsar M, Gottlieb J, Boethig D, Haverich A, Warnecke G. Extended criteria donor lungs and clinical outcome: results of an alternative allocation algorithm. *J Heart Lung Transplant* 2013; **32**: 1065-1072 [PMID: 23953918 DOI: 10.1016/j.healun.2013.06.021]

131 **Barnard JB**, Davies O, Curry P, Catarino P, Dunning J, Jenkins D, Sudarshan C, Nair S, Tsui S, Parmar J. Size matching in lung transplantation: an evidence-based review. *J Heart Lung Transplant* 2013; **32**: 849-860 [PMID: 23953814 DOI: 10.1016/j.healun.2013.07.002]

132 **Chamogeorgakis T**, Mason DP, Murthy SC, Thuita L, Raymond DP, Pettersson GB, Blackstone EH. Impact of nutritional state on lung transplant outcomes. *J Heart Lung Transplant* 2013; **32**: 693-700 [PMID: 23664761 DOI: 10.1016/j.healun.2013.04.005]

133 **Shah P**, Orens JB. Impact of nutritional state on lung transplant outcomes: the weight of the evidence. *J Heart Lung Transplant* 2013; **32**: 755-756 [PMID: 23856213 DOI: 10.1016/j.healun.2013.06.001]

134 **McShane PJ**, Garrity ER. Impact of the lung allocation score. *Semin Respir Crit Care Med* 2013; **34**: 275-280 [PMID: 23821502 DOI: 10.1055/s-0033-1348461]

135 **Wille KM**, Harrington KF, deAndrade JA, Vishin S, Oster RA, Kaslow RA. Disparities in lung transplantation before and after introduction of the lung allocation score. *J Heart Lung Transplant* 2013; **32**: 684-692 [PMID: 23582477 DOI: 10.1016/j.healun.2013.03.005]

136 **Suzuki Y**, Cantu E, Christie JD. Primary graft dysfunction. *Semin Respir Crit Care Med* 2013; **34**: 305-319 [PMID: 23821506 DOI: 10.1055/s-0033-1348474]

137 **Bertani A**. Overcoming primary graft dysfunction after lung transplantation: are we finding our way there? *Transplantation* 2014; **97**: 1100-1101 [PMID: 24573115]

138 **Sommer W**, Tudorache I, Kühn C, Avsar M, Salman J, Ius F, Gras C, Weber P, Welte T, Gottlieb J, Haverich A, Warnecke G. C1-esterase-inhibitor for primary graft dysfunction in lung transplantation. *Transplantation* 2014; **97**: 1185-1191 [PMID: 24573112]

139 **McManigle W**, Pavlisko EN, Martinu T. Acute cellular and antibody-mediated allograft rejection. *Semin Respir Crit Care Med* 2013; **34**: 320-335 [PMID: 23821507 DOI: 10.1055/s-0033-1348471]

140 **Glanville AR**. The role of surveillance bronchoscopy post-lung transplantation. *Semin Respir Crit Care Med* 2013; **34**: 414-420 [PMID: 23821514 DOI: 10.1055/s-0033-1348466]

141 **San Segundo D**, Ballesteros MÁ, Naranjo S, Zurbano F, Miñambres E, López-Hoyos M. Increased numbers of circulating CD8 effector memory T cells before transplantation enhance the risk of acute rejection in lung transplant recipients. *PLoS One* 2013; **8**: e80601 [PMID: 24236187 DOI: 10.1371/journal.pone.0080601]

142 **Krustrup D**, Madsen CB, Iversen M, Engelholm L, Ryder LP, Andersen CB. The number of regulatory T cells in transbronchial lung allograft biopsies is related to FoxP3 mRNA levels in bronchoalveolar lavage fluid and to the degree of acute cellular rejection. *Transpl Immunol* 2013; **29**: 71-75 [PMID: 23969200 DOI: 10.1016/j.trim.2013.08.002]

143 **Husain S**, Resende MR, Rajwans N, Zamel R, Pilewski JM, Crespo MM, Singer LG, McCurry KR, Kolls JK, Keshavjee S, Liles WC. Elevated CXCL10 (IP-10) in bronchoalveolar lavage fluid is associated with acute cellular rejection after human lung transplantation. *Transplantation* 2014; **97**: 90-97 [PMID: 24025324 DOI: 10.1097/TP.0b013e3182a6ee0a]

144 **Lobo LJ**, Aris RM, Schmitz J, Neuringer IP. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. *J Heart Lung Transplant* 2013; **32**: 70-77 [PMID: 23260706 DOI: 10.1016/j.healun.2012.10.007]

145 **Witt CA**, Gaut JP, Yusen RD, Byers DE, Iuppa JA, Bennett Bain K, Alexander Patterson G, Mohanakumar T, Trulock EP, Hachem RR. Acute antibody-mediated rejection after lung transplantation. *J Heart Lung Transplant* 2013; **32**: 1034-1040 [PMID: 23953920 DOI: 10.1016/j.healun.2013.07.004]

146 **Berry G**, Burke M, Andersen C, Angelini A, Bruneval P, Calabrese F, Fishbein MC, Goddard M, Leone O, Maleszewski J, Marboe C, Miller D, Neil D, Padera R, Rassl D, Revello M, Rice A, Stewart S, Yousem SA. Pathology of pulmonary antibody-mediated rejection: 2012 update from the Pathology Council of the ISHLT. *J Heart Lung Transplant* 2013; **32**: 14-21 [PMID: 23260701 DOI: 10.1016/j.healun.2012.11.005]

147 **Snyder LD**, Wang Z, Chen DF, Reinsmoen NL, Finlen-Copeland CA, Davis WA, Zaas DW, Palmer SM. Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients. *Chest* 2013; **144**: 226-233 [PMID: 23328795]

148 **Glanville AR**. Antibody-mediated rejection in lung transplantation: turning myth into reality. *J Heart Lung Transplant* 2013; **32**: 12-13 [PMID: 23260700 DOI: 10.1016/j.healun.2012.11.015]

149 **Weigt SS**, DerHovanessian A, Wallace WD, Lynch JP, Belperio JA. Bronchiolitis obliterans syndrome: the Achilles' heel of lung transplantation. *Semin Respir Crit Care Med* 2013; **34**: 336-351 [PMID: 23821508 DOI: 10.1055/s-0033-1348467]

150 **Saito T**, Takahashi H, Kaneda H, Binnie M, Azad S, Sato M, Waddell TK, Cypel M, Liu M, Keshavjee S. Impact of cytokine expression in the pre-implanted donor lung on the development of chronic lung allograft dysfunction subtypes. *Am J Transplant* 2013; **13**: 3192-3201 [PMID: 24164971 DOI: 10.1111/ajt.12492]

151 **Verleden SE**, Vandermeulen E, Ruttens D, Vos R, Vaneylen A, Dupont LJ, Van Raemdonck DE, Vanaudenaerde BM, Verleden GM. Neutrophilic reversible allograft dysfunction (NRAD) and restrictive allograft syndrome (RAS). *Semin Respir Crit Care Med* 2013; **34**: 352-360 [PMID: 23821509 DOI: 10.1055/s-0033-1348463]

152 **Sato M**, Ohmori-Matsuda K, Saito T, Matsuda Y, Hwang DM, Waddell TK, Singer LG, Keshavjee S. Time-dependent changes in the risk of death in pure bronchiolitis obliterans syndrome (BOS). *J Heart Lung Transplant* 2013; **32**: 484-491 [PMID: 23433813 DOI: 10.1016/j.healun.2013.01.1054]

153 **Sato M**, Hwang DM, Waddell TK, Singer LG, Keshavjee S. Progression pattern of restrictive allograft syndrome after lung transplantation. *J Heart Lung Transplant* 2013; **32**: 23-30 [PMID: 23260703 DOI: 10.1016/j.healun.2012.09.026]

154 **Verleden SE**, Ruttens D, Vandermeulen E, Vaneylen A, Dupont LJ, Van Raemdonck DE, Verleden GM, Vanaudenaerde BM, Vos R. Bronchiolitis obliterans syndrome and restrictive allograft syndrome: do risk factors differ? *Transplantation* 2013; **95**: 1167-1172 [PMID: 23425818 DOI: 10.1097/TP.0b013e318286e076]

155 **Suzuki H**, Lasbury ME, Fan L, Vittal R, Mickler EA, Benson HL, Shilling R, Wu Q, Weber DJ, Wagner SR, Lasaro M, Devore D, Wang Y, Sandusky GE, Lipking K, Pandya P, Reynolds J, Love R, Wozniak T, Gu H, Brown KM, Wilkes DS. Role of complement activation in obliterative bronchiolitis post-lung transplantation. *J Immunol* 2013; **191**: 4431-4439 [PMID: 24043901 DOI: 10.4049/jimmunol.1202242]

156 **Tiriveedhi V**, Banan B, Deepti S, Nataraju A, Hachem R, Trulock E, Alexander PG, Thalachallour M. Role of defensins in the pathogenesis of chronic lung allograft rejection. *Hum Immunol* 2014; **75**: 370-377 [PMID: 24380698 DOI: 10.1016/j.humimm.2013.12.014]

157 **Salvadori M**, Bertoni E. Is it time to give up with calcineurin inhibitors in kidney transplantation? *World J Transplant* 2013; **3**: 7-25 [PMID: 24175203 DOI: 10.5500/wjt.v3.i2.7]

158 **Cornu C**, Dufays C, Gaillard S, Gueyffier F, Redonnet M, Sebbag L, Roussoulières A, Gleissner CA, Groetzner J, Lehmkuhl HB, Potena L, Gullestad L, Cantarovich M, Boissonnat P. Impact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: a systematic review and meta-analysis. *Br J Clin Pharmacol* 2014; **78**: 24-32 [PMID: 24251918 DOI: 10.1111/bcp.12289]

159 **Isakova T**, Xie H, Messinger S, Cortazar F, Scialla JJ, Guerra G, Contreras G, Roth D, Burke GW, Molnar MZ, Mucsi I, Wolf M. Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation. *Am J Transplant* 2013; **13**: 100-110 [PMID: 23025566 DOI: 10.1111/j.1600-6143.2012.04281.x]

160 **Asrani SK**, Wiesner RH, Trotter JF, Klintmalm G, Katz E, Maller E, Roberts J, Kneteman N, Teperman L, Fung JJ, Millis JM. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. *Am J Transplant* 2014; **14**: 356-366 [PMID: 24456026 DOI: 10.1111/ajt.12543]

161 **Saliba F**, De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Jonas S, Sudan D, Fischer L, Duvoux C, Chavin KD, Koneru B, Huang MA, Chapman WC, Foltys D, Dong G, Lopez PM, Fung J, Junge G. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. *Am J Transplant* 2013; **13**: 1734-1745 [PMID: 23714399 DOI: 10.1111/ajt.12280]

162 **Junge G**, Dumortier T, Schwende H, Fung J. mTOR inhibition in liver transplantation: how to dose for effective/safe CNI reduction? *Transplant Proc* 2013; **45**: 1979-1980 [PMID: 23769088 DOI: 10.1016/j.transproceed.2013.02.102]

163 **Bhat M**, Charlton M. Preserving flow in liver transplant recipients: mTOR inhibitors everolimus and sirolimus are not peas from a pod. *Am J Transplant* 2013; **13**: 1633-1635 [PMID: 23802724 DOI: 10.1111/ajt.12290]

164 **Sterneck M**, Kaiser GM, Heyne N, Richter N, Rauchfuss F, Pascher A, Schemmer P, Fischer L, Klein CG, Nadalin S, Lehner F, Settmacher U, Neuhaus P, Gotthardt D, Loss M, Ladenburger S, Paulus EM, Mertens M, Schlitt HJ. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. *Am J Transplant* 2014; **14**: 701-710 [PMID: 24502384 DOI: 10.1111/ajt.12615]

165 **Levitsky J**, Feng S. Sirolimus and mTOR inhibitors in liver transplantation: the wheel has come full circle. *Am J Transplant* 2014; **14**: 249-250 [PMID: 24620373 DOI: 10.1111/ajt.12545]

166 **Matsuo Y**, Cassar A, Yoshino S, Flammer AJ, Li J, Gulati R, Topilsky Y, Raichlin E, Lennon RJ, Lerman LO, Rihal CS, Kushwaha SS, Lerman A. Attenuation of cardiac allograft vasculopathy by sirolimus: Relationship to time interval after heart transplantation. *J Heart Lung Transplant* 2013; **32**: 784-791 [PMID: 23856215 DOI: 10.1016/j.healun.2013.05.015]

167 **Witt CA**, Hachem RR. Immunosuppression: what's standard and what's new? *Semin Respir Crit Care Med* 2013; **34**: 405-413 [PMID: 23821513 DOI: 10.1055/s-0033-1348465]

168 **Gurk-Turner C**, Manitpisitkul W, Cooper M. A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor. *Transplantation* 2012; **94**: 659-668 [PMID: 22986894 DOI: 10.1097/TP.0b013e31825b411c]

169 **Da Dalt L**, Bressan S, Martinolli F, Perilongo G, Baraldi E. Treatment of bronchiolitis: state of the art. *Early Hum Dev* 2013; **89 Suppl 1**: S31-S36 [PMID: 23809346 DOI: 10.1016/S0378-3782(13)70011-2]

170 **Sacher VY**, Fertel D, Srivastava K, Panos A, Nguyen D, Baxter T, Shafazand S, Pham SM. Effects of prophylactic use of sirolimus on bronchiolitis obliterans syndrome development in lung transplant recipients. *Ann Thorac Surg* 2014; **97**: 268-274 [PMID: 24119986 DOI: 10.1016/j.athoracsur.2013.07.072]

171 **Borro JM**. Advances in immunosuppression after lung transplantation. *Med Intensiva* 2013; **37**: 44-49 [PMID: 22854620 DOI: 10.1016/j.medin.2012.05.011]

172 **Iacono AT**, Johnson BA, Grgurich WF, Youssef JG, Corcoran TE, Seiler DA, Dauber JH, Smaldone GC, Zeevi A, Yousem SA, Fung JJ, Burckart GJ, McCurry KR, Griffith BP. A randomized trial of inhaled cyclosporine in lung-transplant recipients. *N Engl J Med* 2006; **354**: 141-150 [PMID: 16407509 DOI: 10.1056/NEJMoa043204]

173 **Whitford H**, Walters EH, Levvey B, Kotsimbos T, Orsida B, Ward C, Pais M, Reid S, Williams T, Snell G. Addition of inhaled corticosteroids to systemic immunosuppression after lung transplantation: a double-blind, placebo-controlled trial. *Transplantation* 2002; **73**: 1793-1799 [PMID: 12085003]

174 **Johnson BA**, Iacono AT, Zeevi A, McCurry KR, Duncan SR. Statin use is associated with improved function and survival of lung allografts. *Am J Respir Crit Care Med* 2003; **167**: 1271-1278 [PMID: 12615629 DOI: 10.1164/rccm.200205-410OC]

175 **Vos R**, Vanaudenaerde BM, Verleden SE, Ruttens D, Vaneylen A, Van Raemdonck DE, Dupont LJ, Verleden GM. Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection. *Transplantation* 2012; **94**: 101-109 [PMID: 22461039 DOI: 10.1097/TP.0b013e31824db9da]

176 **Penninga L**, Møller CH, Gustafsson F, Gluud C, Steinbrüchel DA. Immunosuppressive T-cell antibody induction for heart transplant recipients. *Cochrane Database Syst Rev* 2013; **12**: CD008842 [PMID: 24297433 DOI: 10.1002/14651858.CD008842]

177 **Stratta RJ**, Farney AC, Rogers J, Orlando G. Immunosuppression for pancreas transplantation with an emphasis on antibody induction strategies: review and perspective. *Expert Rev Clin Immunol* 2014; **10**: 117-132 [PMID: 24236648 DOI: 10.1586/1744666X.2014.853616]

178 **Mako M**, Hager D, Muth B, Kaufman D, Ellis T, Djamali A. Thymoglobulin is associated with a significant reduction in de novo donor-specific antibodies and antibody mediated rejection in moderately sensitized renal transplant recipients. *Am J Transplant* 2013; **13**: S113

179 **Morgan RD**, O'Callaghan JM, Knight SR, Morris PJ. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. *Transplantation* 2012; **93**: 1179-1188 [PMID: 22660659 DOI: 10.1097/TP.0b013e318257ad41]

180 **Barnett AN**, Hadjianastassiou VG, Mamode N. Rituximab in renal transplantation. *Transpl Int* 2013; **26**: 563-575 [PMID: 23414100 DOI: 10.1111/tri.12072]

181 **Kohei N**, Hirai T, Omoto K, Ishida H, Tanabe K. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. *Am J Transplant* 2012; **12**: 469-476 [PMID: 22054413 DOI: 10.1111/j.1600-6143.2011.03830.x]

182 **Sautenet B**, Blancho G, Buchler M. One year results of the effects of rituximab on acute humoral rejection in renal transplantation: RITUX ERAH, a multicenter randomized placebo controlled trial. *Am J Transplant* 2013; **13** (S5): S112

183 **Stegall MD**, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. *Am J Transplant* 2011; **11**: 2405-2413 [PMID: 21942930 DOI: 10.1111/j.1600-6143.2011.03757.x]

184 ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available at: http: //www.clinicaltrials.gov/. Accessed June 3, 2013

185 **Fehr T**, Gaspert A. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. *Transpl Int* 2012; **25**: 623-632 [PMID: 22394269 DOI: 10.1111/j.1432-2277.2012.01453.x]

186 **Page EK**, Dar WA, Knechtle SJ. Biologics in organ transplantation. *Transpl Int* 2012; **25**: 707-719 [PMID: 22420711 DOI: 10.1111/j.1432-2277.2012.01456.x]

187 **Charpentier B**, Medina Pestana JO, Del C Rial M, Rostaing L, Grinyó J, Vanrenterghem Y, Matas A, Zhang R, Mühlbacher F, Pupim L, Florman S. Long-term exposure to belatacept in recipients of extended criteria donor kidneys. *Am J Transplant* 2013; **13**: 2884-2891 [PMID: 24103072 DOI: 10.1111/ajt.12459]

188 **Rostaing L**, Vincenti F, Grinyó J, Rice KM, Bresnahan B, Steinberg S, Gang S, Gaite LE, Moal MC, Mondragón-Ramirez GA, Kothari J, Pupim L, Larsen CP. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. *Am J Transplant* 2013; **13**: 2875-2883 [PMID: 24047110 DOI: 10.1111/ajt.12460]

189 **Kirk AD**, Guasch A, Xu H, Cheeseman J, Mead SI, Ghali A, Mehta AK, Wu D, Gebel H, Bray R, Horan J, Kean LS, Larsen CP, Pearson TC. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. *Am J Transplant* 2014; **14**: 1142-1151 [PMID: 24684552 DOI: 10.1111/ajt.12712]

190 **Goldwater R**, Keirns J, Blahunka P, First R, Sawamoto T, Zhang W, Kowalski D, Kaibara A, Holman J. A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects. *Am J Transplant* 2013; **13**: 1040-1046 [PMID: 23356210 DOI: 10.1111/ajt.12082]

191 **Watanabe M**, Yamashita K, Suzuki T, Kamachi H, Kuraya D, Koshizuka Y, Ogura M, Yoshida T, Aoyagi T, Fukumori D, Shimamura T, Okimura K, Maeta K, Miura T, Sakai F, Todo S. ASKP1240, a fully human anti-CD40 monoclonal antibody, prolongs pancreatic islet allograft survival in nonhuman primates. *Am J Transplant* 2013; **13**: 1976-1988 [PMID: 23841873 DOI: 10.1111/ajt.12330]

192 **Rostaing L**, Charpentier B, Glyda M, Rigotti P, Hettich F, Franks B, Houbiers JG, First R, Holman JM. Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. *Am J Transplant* 2013; **13**: 1724-1733 [PMID: 23730730 DOI: 10.1111/ajt.12303]

193 **Vincenti F**, Tedesco Silva H, Busque S, O'Connell P, Friedewald J, Cibrik D, Budde K, Yoshida A, Cohney S, Weimar W, Kim YS, Lawendy N, Lan SP, Kudlacz E, Krishnaswami S, Chan G. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. *Am J Transplant* 2012; **12**: 2446-2456 [PMID: 22682022 DOI: 10.1111/j.1600-6143.2012.04127.x]

194 **Wojciechowski D**, Vincenti F. Tofacitinib in kidney transplantation. *Expert Opin Investig Drugs* 2013; **22**: 1193-1199 [PMID: 23841583 DOI: 10.1517/13543784.2013.811231]

195 **Russ GR**, Tedesco-Silva H, Kuypers DR, Cohney S, Langer RM, Witzke O, Eris J, Sommerer C, von Zur-Mühlen B, Woodle ES, Gill J, Ng J, Klupp J, Chodoff L, Budde K. Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results. *Am J Transplant* 2013; **13**: 1746-1756 [PMID: 23668931 DOI: 10.1111/ajt.12251]

196 **Tedesco-Silva H**, Kho MM, Hartmann A, Vitko S, Russ G, Rostaing L, Budde K, Campistol JM, Eris J, Krishnan I, Gopalakrishnan U, Klupp J. Sotrastaurin in calcineurin inhibitor-free regimen using everolimus in de novo kidney transplant recipients. *Am J Transplant* 2013; **13**: 1757-1768 [PMID: 23659755 DOI: 10.1111/ajt.12255]

197 **Kimelman M**, Brandacher G. Trends in immunosuppression after pancreas transplantation: what is in the pipeline? *Curr Opin Organ Transplant* 2013; **18**: 76-82 [PMID: 23254700 DOI: 10.1097/MOT.0b013e32835c6eda]

198 **Samikannu B**, Chen C, Lingwal N, Padmasekar M, Engel FB, Linn T. Dipeptidyl peptidase IV inhibition activates CREB and improves islet vascularization through VEGF-A/VEGFR-2 signaling pathway. *PLoS One* 2013; **8**: e82639 [PMID: 24349326 DOI: 10.1371/journal.pone.0082639]

199 **Vos R**, Verleden SE, Ruttens D, Vandermeulen E, Yserbyt J, Dupont LJ, Van Raemdonck DE, De Raedt N, Gheysens O, De Jong PA, Verleden GM, Vanaudenaerde BM. Pirfenidone: a potential new therapy for restrictive allograft syndrome? *Am J Transplant* 2013; **13**: 3035-3040 [PMID: 24102752 DOI: 10.1111/ajt.12474]

200 **Bonarius HP**, Baas F, Remmerswaal EB, van Lier RA, ten Berge IJ, Tak PP, de Vries N. Monitoring the T-cell receptor repertoire at single-clone resolution. *PLoS One* 2006; **1**: e55 [PMID: 17183685 DOI: 10.1371/journal.pone.0000055]

201 **Levitsky J**. Operational tolerance: past lessons and future prospects. *Liver Transpl* 2011; **17**: 222-232 [PMID: 21384504 DOI: 10.1002/lt.22265]

202 **Ruiz P**, Maldonado P, Hidalgo Y, Gleisner A, Sauma D, Silva C, Saez JJ, Nuñez S, Rosemblatt M, Bono MR. Transplant tolerance: new insights and strategies for long-term allograft acceptance. *Clin Dev Immunol* 2013; **2013**: 210506 [PMID: 23762087 DOI: 10.1155/2013/210506]

203 **Sachs DH**, Sykes M, Kawai T, Cosimi AB. Immuno-intervention for the induction of transplantation tolerance through mixed chimerism. *Semin Immunol* 2011; **23**: 165-173 [PMID: 21839648 DOI: 10.1016/j.smim.2011.07.001]

204 **Kawai T**, Sachs DH, Sykes M, Cosimi AB. HLA-mismatched renal transplantation without maintenance immunosuppression. *N Engl J Med* 2013; **368**: 1850-1852 [PMID: 23656665 DOI: 10.1056/NEJMc1213779]

205 **Farris AB**, Taheri D, Kawai T, Fazlollahi L, Wong W, Tolkoff-Rubin N, Spitzer TR, Iafrate AJ, Preffer FI, Locascio SA, Sprangers B, Saidman S, Smith RN, Cosimi AB, Sykes M, Sachs DH, Colvin RB. Acute renal endothelial injury during marrow recovery in a cohort of combined kidney and bone marrow allografts. *Am J Transplant* 2011; **11**: 1464-1477 [PMID: 21668634 DOI: 10.1111/j.1600-6143.2011.03572.x]

206 **Kawai T**, Sogawa H, Boskovic S, Abrahamian G, Smith RN, Wee SL, Andrews D, Nadazdin O, Koyama I, Sykes M, Winn HJ, Colvin RB, Sachs DH, Cosimi AB. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. *Am J Transplant* 2004; **4**: 1391-1398 [PMID: 15307826 DOI: 10.1111/j.1600-6143.2004.00523.x]

207 **Wekerle T**, Kurtz J, Ito H, Ronquillo JV, Dong V, Zhao G, Shaffer J, Sayegh MH, Sykes M. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. *Nat Med* 2000; **6**: 464-469 [PMID: 10742157 DOI: 10.1038/74731]

208 **Kawai T**, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, Shaffer J, Preffer FI, Ding R, Sharma V, Fishman JA, Dey B, Ko DS, Hertl M, Goes NB, Wong W, Williams WW, Colvin RB, Sykes M, Sachs DH. HLA-mismatched renal transplantation without maintenance immunosuppression. *N Engl J Med* 2008; **358**: 353-361 [PMID: 18216355 DOI: 10.1056/NEJMoa071074]

209 **Adams AB**, Williams MA, Jones TR, Shirasugi N, Durham MM, Kaech SM, Wherry EJ, Onami T, Lanier JG, Kokko KE, Pearson TC, Ahmed R, Larsen CP. Heterologous immunity provides a potent barrier to transplantation tolerance. *J Clin Invest* 2003; **111**: 1887-1895 [PMID: 12813024 DOI: 10.1172/JCI200317477]

210 **Casiraghi F**, Perico N, Remuzzi G. Mesenchymal stromal cells to promote solid organ transplantation tolerance. *Curr Opin Organ Transplant* 2013; **18**: 51-58 [PMID: 23254705 DOI: 10.1097/MOT.0b013e32835c5016]

211 **Leventhal J**, Abecassis M, Miller J, Gallon L, Ravindra K, Tollerud DJ, King B, Elliott MJ, Herzig G, Herzig R, Ildstad ST. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. *Sci Transl Med* 2012; **4**: 124ra28 [PMID: 22399264 DOI: 10.1126/scitranslmed.3003509]

212 **Leventhal J**, Abecassis M, Miller J, Gallon L, Tollerud D, Elliott MJ, Bozulic LD, Houston C, Sustento-Reodica N, Ildstad ST. Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome. *Transplantation* 2013; **95**: 169-176 [PMID: 23222893 DOI: 10.1097/TP.0b013e3182782fc1]

213 **Leventhal JR**, Mathew JM, Salomon DR, Kurian SM, Suthanthiran M, Tambur A, Friedewald J, Gallon L, Charette J, Levitsky J, Kanwar Y, Abecassis M, Miller J. Genomic biomarkers correlate with HLA-identical renal transplant tolerance. *J Am Soc Nephrol* 2013; **24**: 1376-1385 [PMID: 23787913 DOI: 10.1681/ASN.2013010068]

214 **Cippà PE**, Gabriel SS, Kraus AK, Chen J, Wekerle T, Guimezanes A, Wüthrich RP, Fehr T. Bcl-2 inhibition to overcome memory cell barriers in transplantation. *Am J Transplant* 2014; **14**: 333-342 [PMID: 24472193 DOI: 10.1111/ajt.12554]

215 **Lau AH**, de Creus A, Lu L, Thomson AW. Liver tolerance mediated by antigen presenting cells: fact or fiction? *Gut* 2003; **52**: 1075-1078 [PMID: 12865260]

216 **Warren A**, Le Couteur DG, Fraser R, Bowen DG, McCaughan GW, Bertolino P. T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells. *Hepatology* 2006; **44**: 1182-1190 [PMID: 17058232 DOI: 10.1002/hep.21378]

217 **McAvoy EF**, Kubes P. Holey endothelium: gateways for naïve T cell activation. *Hepatology* 2006; **44**: 1083-1085 [PMID: 17058224 DOI: 10.1002/hep.21421]

218 **Wu SL**, Pan CE. Tolerance and chimerism and allogeneic bone marrow/stem cell transplantation in liver transplantation. *World J Gastroenterol* 2013; **19**: 5981-5987 [PMID: 24106398 DOI: 10.3748/wjg.v19.i36.5981]

219 . Blumberg EA, Danziger-Isakov L, Kumar D, Michaels MG, Razonable RR.Editors. The American Society of Transplantation Infectious Diseases Guidelines 3rd Edition Am J Transplant 2013; 13, S 4: 1–371[DOI: 10.1111/ajt.12129]

220 **Seem DL**, Lee I, Umscheid CA, Kuehnert MJ. Excerpt from PHS guideline for reducing HIV, HBV and HCV transmission through organ transplantation. *Am J Transplant* 2013; **13**: 1953-1962 [PMID: 23890284 DOI: 10.1111/ajt.12386]

221 **Kotton CN**, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. *Transplantation* 2013; **96**: 333-360 [PMID: 23896556 DOI: 10.1097/TP.0b013e31829df29d]

222 **Fishman JA**. Overview: cytomegalovirus and the herpesviruses in transplantation. *Am J Transplant* 2013; **13 Suppl 3**: 1-8; quiz 8 [PMID: 23347210 DOI: 10.1111/ajt.12002]

223 **Humar A**, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. *Am J Transplant* 2006; **6**: 262-274 [PMID: 16426310 DOI: 10.1111/j.1600-6143.2005.01207.x]

224 **Green M**. Introduction: Infections in solid organ transplantation. *Am J Transplant* 2013; **13 Suppl 4**: 3-8 [PMID: 23464993 DOI: 10.1111/ajt.12093]

225 **Theodoropoulos N**, Jaramillo A, Ladner DP, Ison MG. Deceased organ donor screening for HIV, hepatitis B, and hepatitis C viruses: a survey of organ procurement organization practices. *Am J Transplant* 2013; **13**: 2186-2190 [PMID: 23711196 DOI: 10.1111/ajt.12260]

226 **Orlowski J**, Alexander C, Ison M, Rosendale J, Chabalewski F. NAT Survey Workgroup, Richmond, VA. Nucleic Acid Testing (NAT) for HIV, HBV, and HCV: Current Practices of 58 US Organ Procurement Organizations (OPOs). *Am J Transplant* 2009; **9**: S2 197 [DOI: 10.1111/j.1600-6143.2009.02658.x]

227 **Rogers MF**, Simonds RJ, Lawton KE, Moseley RR, Jones WK. Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. *MMWR Recomm Rep* 1994; **43**: 1-17

228 Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products. August 2007 Available at: http: //www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm091345.pdf

229 **Hirsch HH**, Randhawa P. BK polyomavirus in solid organ transplantation. *Am J Transplant* 2013; **13 Suppl 4**: 179-188 [PMID: 23465010 DOI: 10.1111/ajt.12110]

230 **Sood P**, Senanayake S, Sujeet K, Medipalli R, Van-Why SK, Cronin DC, Johnson CP, Hariharan S. Donor and recipient BKV-specific IgG antibody and posttransplantation BKV infection: a prospective single-center study. *Transplantation* 2013; **95**: 896-902 [PMID: 23511214 DOI: 10.1097/TP.0b013e318282ba83]

231 **Greiner M**, Cusini A, Ruesch M, Schiesser M, Ledergerber B, Fehr T, Mueller NJ. A stringent preemptive protocol reduces cytomegalovirus disease in the first 6 months after kidney transplantation. *Infection* 2012; **40**: 669-675 [PMID: 23015480 DOI: 10.1007/s15010-012-0343-5]

232 **Griffiths PD**, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O'Beirne J, Thorburn D, Patch D, Atkinson CE, Pichon S, Sweny P, Lanzman M, Woodford E, Rothwell E, Old N, Kinyanjui R, Haque T, Atabani S, Luck S, Prideaux S, Milne RS, Emery VC, Burroughs AK. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. *Lancet* 2011; **377**: 1256-1263 [PMID: 21481708 DOI: 10.1016/S0140-6736(11)60136-0]

233 **Kharfan-Dabaja MA**, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, Guterwill DF, Smith LR, Rolland AP, Kenney RT. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Infect Dis* 2012; **12**: 290-299 [PMID: 22237175 DOI: 10.1016/S1473-3099(11)70344-9]

234 **Carbone M**, Mutimer D, Neuberger J. Hepatitis C virus and nonliver solid organ transplantation. *Transplantation* 2013; **95**: 779-786 [PMID: 23172130 DOI: 10.1097/TP.0b013e318273fec4]

235 **Xiao D**, Craig JC, Chapman JR, Dominguez-Gil B, Tong A, Wong G. Donor cancer transmission in kidney transplantation: a systematic review. *Am J Transplant* 2013; **13**: 2645-2652 [PMID: 24034231 DOI: 10.1111/ajt.12430]

236 **Desai R**, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J. Cancer transmission from organ donors-unavoidable but low risk. *Transplantation* 2012; **94**: 1200-1207 [PMID: 23269448 DOI: 10.1097/TP.0b013e318272df41]

237 **Desai R**, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J. Death on waiting-list and risk of transmission of cancer: where is the right balance? *Am J Transplant* 2013; **13** (suppl 5): S140

238 **Desai R**, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J. Estimated risk of cancer transmission from organ donor to graft recipient in a national transplantation registry. *Br J Surg* 2014; **101**: 768-774 [PMID: 24771410 DOI: 10.1002/bjs.9460]

239 **Engels E**. Risk for transmission of cancer from solid organ donors in the United States. *Am J Transplant 2013*; 13 (suppl 5): S536

240 **Engels EA**, Castenson D, Pfeiffer RM, Kahn A, Pawlish K, Goodman MT, Nalesnik MA, Israni AK, Snyder J, Kasiske B. Cancers among US organ donors: a comparison of transplant and cancer registry diagnoses. *Am J Transplant* 2014; **14**: 1376-1382 [PMID: 24712385 DOI: 10.1111/ajt.12683]

241 **Desai R**, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J. Risk of recurrence of preexisting cancer in organ recipients. *Am J Transplant* 2013; **13** (suppl 5): S98

242 **Sampaio MS**, Cho YW, Qazi Y, Bunnapradist S, Hutchinson IV, Shah T. Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. National Transplant Database. *Transplantation* 2012; **94**: 990-998 [PMID: 23085553 DOI: 10.1097/TP.0b013e318270bc7b]

243 **Na R**, Grulich AE, Meagher NS, McCaughan GW, Keogh AM, Vajdic CM. Comparison of de novo cancer incidence in Australian liver, heart and lung transplant recipients. *Am J Transplant* 2013; **13**: 174-183 [PMID: 23094788 DOI: 10.1111/j.1600-6143.2012.04302.x]

244 **Cho Y**, Sampaio M, Shah T, Qazi Y, Fong T, Hutchinson IV. Association between de novo post-transplant nonmelanoma skin cancer and solid tumor after organ transplantation – an analysis of OPTN/UNOS data. *Am J Transplant* 2013; **13** (suppl 5): S536

245 **McDonald S**, Carroll R. The occurrence of non-melanoma skin cancer predicts risk of subsequent solid organ cancer. *Am J Transplant* 2013; **13** (suppl 5): S97

246 **Hanlon A**, Colegio OR. The cutting edge of skin cancer in transplant recipients: scientific retreat of international transplant Skin Cancer Collaborative and Skin Cancer in Organ Transplant Patients Europe. *Am J Transplant* 2014; **14**: 1012-1015 [PMID: 24612476 DOI: 10.1111/ajt12681]

**P-Reviewer:** **Furka A,** Gong JP, Sipos F, Wang GY **S-Editor:** Wen LL **L-Editor: E-Editor:**